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Abstract 
 
Ethanol is one of the most well studied and researched drugs available to man and the effects of 
ethanol on the human body are of particular interest with the effects on decision making and 
reaction times in relation to driving being a key area of research, with legislation relating to levels of 
alcohol within the human body which can be considered safe for vehicle operation being written as a 
direct result of these studies.  Analysis of blood and urine alcohol content is one of the most 
common forensic toxicological analyses carried out and methods developed to quantify and detect 
alcohol in biological samples such as blood and urine are vital in areas such as road traffic toxicology 
where an accurate and trustworthy quantitation is required to determine if a suspected drunk driver 
is in fact under the influence of alcohol whilst in charge of a vehicle. The method development and 
validation process are designed to demonstrate the capability of an analytical instrument to achieve 
this quantitation. A method was developed using headspace gas chromatography with flame 
ionisation detection (HS- GC-FID) using an HTA 200 H headspace auto sampler, BAC plus 1 and plus 2 
columns and dual FID 2014 detectors and tertiary butanol as an internal standard. The accuracy, 
precision and parameters such as linearity were tested and validated according to a pre- determined 
validation plan. It was determined that a separation of ethanol and acetone was achieved on one 
column and the accuracy and precision is within the set parameters of the validation plan. The 
method was successfully validated, and the next step of the experimentation was the testing of 
storage stability which involved testing the stability of blood, urine and QC samples at room 
temperature for up to one month and the testing of freeze thaw stability for up to two-cycles. It was 
determined that most samples were stable throughout the stability testing period and there was 
largely no significant effect on alcohol concentration throughout the testing phases. 
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Introduction 
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The History, chemical structure and pharmacology of alcohol 
 
Ethanol, also known as ethyl alcohol or grain alcohol has a long history of consumption and abuse 
within human society throughout the world. It has been shown to have medical applications and was 
viewed as a treatment for ailments with alcohol being termed “Aqua vitae” or water of life by monks 
and physicians of the middle ages (Seward, 1979). It has also been consumed as an alternative to 
contaminated water (Crews, 2018) or to protect from diseases such as the bubonic plague (Hanson, 
1995). It is difficult to pinpoint when exactly humans began distilling alcohol for consumption, the 
earliest evidence of alcohol brewing was found as ethanol residues in pottery from china dating 
around 7000 to 6600 BC and an alcoholic drink from distilled rice was identified in India known as Sura 
from between 3000 and 2000 BC (Mandelbaum, 1965) with evidence of alcohol brewing by the 
Sumerians in Mesopotamia. At around the same time vineyards in Ancient Greece became one of the 
earliest recorded producers of wine and providing wine to guests as an act of hospitality became 
commonplace (Scott, 2015). Many of these   Greek traditions of wine production and festivities related 
to alcohol consumption translated over into Roman cultures with wine playing a big role in their 
society, it was also used in medical applications within the Roman Empire. Wine also played a role in 
religion within the Roman Empire with a cult to the Roman and Greek god Dionysus/Bacchus being 
formed and spreading throughout the society of the empire (Scott, 2015). By the 1400s, spirits were 
beginning to be distilled with whiskey, gin and rum being referenced around this period and by 1494 
whiskey within Scotland appeared to be well established with records of consumption being recorded 
in the UK Exchequer accounts (Bower, 2016). 
Ethanol is a polar primary alcohol with the formula C2H6O (Figure 1). It is a clear colourless liquid with 
a distinctive odour and taste with a melting point of -173.4oF (-114.1 oC) and a boiling point of 173.3 ° 
F (78.5 oC) (Silberberg, 2015). It is produced as a product of plant fermentation of sugars or starch and 
can also be produced via the hydration of ethylene (Chang, 2016). Ethanol has many useful 
applications including use in cosmetic products, dyes, explosives and synthetic drugs (Chang, 2016). 
In addition, ethanol is often mixed into beverages for recreational consumption, and ethanol can 
induce significant effects on the central nervous system (CNS) dependent on the dose. Once ingested 
the pathway of detoxification and removal from the body takes place in four major steps according to 
the principle of pharmacokinetics which are defined under the acronym ADME; (absorption, 
distribution, metabolism and elimination). The rate which this process takes place is dependent on a 
host of factors including age, gender, metabolic rate and nutrition.  
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Figure 1: A 3-D representation of a molecule of ethanol, the OH group represents the polar section of 
the molecule, with the CH4 section representing the non-polar section. 
Absorption takes place primarily in the gastrointestinal tract, alcohol is absorbed slowly through the 
stomach and rapidly through the small intestine, and this is due to the larger surface area of the 
intestinal tract when compared to that of the stomach. The rate at which ethanol is absorbed depends 
on two major factors. The gastric emptying rate, which is the rate at which the stomach empties its 
contents, if the stomach is empty prior to consuming alcohol, such as following a period  of fasting for 
example, the gastric emptying rate will be higher thus ethanol absorption will occur more rapidly 
(Gentry, 2000). Nutrients such as carbohydrates, fats and proteins will slow the rate of gastric 
emptying increasing the time taken for ethanol to transfer from the stomach to the duodenum. 
(Gentry, 2000). The second major factor is the concentration of ethanol ingested (Dubowski, 1985). 
Upon absorption ethanol enters the portal vein and is transported to the liver, where it undergoes a 
phenomenon known as the first pass effect or first pass metabolism, which is the uptake and 
metabolism of a substance within the liver before entering (the) systemic circulation (Gentry, 2000). 
There is a connection between gender and the rate of first pass metabolism, it is believed that males 
have a higher first pass metabolism rate (although the gender difference in practice is minor) (Ammon 
et al., 1996) when compared to females which is caused by a lower gastric alcohol dehydrogenase 
(ADH) (Seitz et al., 1993). This corresponds to a slightly higher tolerance to alcohol in men. When 
absorption of ethanol into a cell occurs it is facilitated by diffusion (Lodish, 2013), a passive process 
meaning it does not require any transport molecules to facilitate the action, which is defined as the 
movement of a substance from an area of high concentration to an area of low concentration 
according to Fick’s Law (Lodish, 2013).  
After absorption from the gastrointestinal tract and first pass metabolism, ethanol enters systemic 
circulation and is transported to the right side of the heart, following on to the lungs and then 
following the circulation back to the heart where it then travels throughout the circulatory system  
organs with a higher blood flow rate and water content such as the brain will receive ethanol from the 
blood at a higher rate than tissues and organs that have a lower blood flow such as skeletal muscle 
(Jones,2011). Ethanol also distributes into the total body water which for an average male of 70 Kg is 
said to be 42 litres (42 Kg) of water distributed throughout the body, approximately 60% of the body 
mass is attributed to water with up to a third of the total body water being found in the extra cellular 
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fluid component (Rosenfield, 1996). This high-water content is responsible for ethanol’s widespread 
distribution in the body. 
Ethanol like most drugs is primarily metabolised by the liver. The metabolic pathway responsible for 
ethanol metabolism has two major branches within humans, the first involves the enzymatic 
breakdown of ethanol into acetaldehyde by the enzyme alcohol dehydrogenase (figure 2). This uses 
NAD+ as a cofactor which is reduced into NADH in the process, Zinc also plays a role in this function, 
it acts as a guide to position the ethanol within the active site (Goodsell, 2001). This process is detailed 
in figure 3. The primary  enzyme implicated in ethanol metabolism is  ADHI ( Alcohol dehydrogenase 
class I), this has the highest affinity for ethanol when compared to the class II and III isoforms of ADH, 
although these will bind more readily to ethanol in higher BACs (Blood alcohol concentrations) 
(Ramchandani, 2013). Acetaldehyde is a toxic metabolite which is a possible cause of hangover 
symptoms (Swift, 1998), although other possible causes such as a disturbance in electrolyte balance 
or other biologically active compounds or congeners such as methanol have been suggested. It is also 
possible that a hypoglycaemic episode may be responsible for the headache and disorientation 
symptoms exhibited during a hangover, although the exact cause is unknown it is possibly a mixture 
of one or more of these factors (Swift, 1998). Alcohol is also a diuretic and suppresses the activity of 
anti-diuretic hormone within the kidney resulting in an increased urinary output, in events of extended 
drinking with no proportional water consumption this can lead to dehydration which can contribute 
to the headaches experienced with a hangover (Rang et al., 2016). It is important for acetaldehyde to 
be metabolised quickly to avoid toxicity, acetaldehyde is processed into acetate by the enzyme ALDH 
(aldehyde dehydrogenase). It is shown that individuals of Asian descent can possess variants of the 
ADH and ALDH genes which makes the metabolism of acetaldehyde less efficient resulting in a build- 
up of the metabolite causing a phenomenon known as alcohol flush response (Jones, 2011). The 
symptoms of alcohol flush response include redness of the skin around the face, neck and occasionally 
the entire body; this is a result of vasodilation caused by the acetaldehyde build-up. The resulting 
metabolic process within the liver also disrupts the NAD+ and NADH balances within the liver with an 
increase being observed in both cytosolic and mitochondrial fractions resulting in a disturbance in 
other metabolic processes and functions, such as the metabolism of certain drugs. (Rang et al., 2016). 
Acetate may be processed within the liver or enter the bloodstream and be processed within 
peripheral tissues. The eventual end point of metabolism in this pathway takes place in the muscle 
tissue and the end products are carbon dioxide and water, methanol follows the same metabolic 
pathway and is metabolised into formaldehyde and then to formic acid (Zimmerman, 1999).  
The second pathway which plays a lesser role in the metabolism of ethanol, and usually only 
contributes during higher blood alcohol concentrations or chronic episodes of alcohol consumption 
are encountered is the microsomal oxidative pathway. This pathway uses the cytochrome P450 
enzyme CYP2E1 which is located in the smooth endoplasmic reticulum. This pathway leads to the 
production of Reactive Oxygen Species (ROS) and plays a role in metabolism of ethanol into 
acetaldehyde.  
Only a small proportion of ethanol is excreted unchanged and the process of excretion may happen 
through three routes, urine, sweat and exhalation. Jones et al., 2009 estimates that only around 2% 
of ethanol is excreted in the urine unchanged (Jones et al., 2009). Ethanol elimination is believed to 
follow zero-order kinetics, which means it is dose independent (Baselt, 1995), the elimination rate of 
ethanol has been estimated to be between 10-15ml of absolute alcohol per hour for a non-tolerant 
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person (Leonard, 2005) with 18 mg being shown as a lower elimination rate for a person considered 
to be tolerant (Wilkens et al., 1998). A small proportion of ethanol is conjugated into ethyl glucuronide, 
ethyl sulphate or ethyl esters. Ethyl glucuronide is formed as a minor metabolite of ethanol by the 
enzyme UDP-glucuronosyltransferase whilst ethyl sulphate is formed by sulfotransferase and although 
this and sweat does account for a portion of the elimination of ethanol overall this only accounts for 
a small fraction of elimination. Around 90% of ethanol ingested is eliminated via the oxidative 
metabolic pathways and under 10% of the total elimination occurs via sweat, urine or breath 
(Cederbaum, 2013).  
 
Figure 2: The oxidative reaction pathway for the elimination of ethanol showing the oxidation of 
ethanol by ADH into acetaldehyde and the second oxidation stage which is the oxidation of 
acetaldehyde into acetate (Kawaratani, 2013). 
 
Figure 3:  The molecular representation showing the role zinc plays in anchoring ethanol in the active 
site of ADH during the enzymatic metabolism of ethanol into acetaldehyde (Goodsell, 2001). As 
shown, this process utilises NAD+ and the molecule used in this metabolism is no longer available for 
other metabolic processes such as metabolism of medicinal drugs demonstrating the disruptive effect 
of ethanol on liver metabolic activity. 
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Alcohol on the CNS 
 
The effects of alcohol concentration on an individual were examined in a seminal study by Kurt 
Dubowski in 1977. This study documented the stages of alcohol intoxication, the clinical effects 
observed and the BAC range at which the specific states are experienced. It has been noted that 
consistent intake of small volumes of alcohol, one or two units a day rapidly leads to a tolerance build 
–up, however this tolerance is rapidly lost within only a few days of abstinence (Leonard, 2005). Table 
1 demonstrates these stages with conversions of the original BAC values which were given as a 
percentage into mg/dl, the unit currently used by the UK. The blood alcohol content at which inhibition 
of response times and fine performance tasks occurs, happens at relatively low levels of ethanol 
starting at as low as 30 mg/dl and it has been shown that these effects are more prominent as alcohol 
levels are increasing as opposed to when they are decreasing. This effect is known as the Mellanby 
effect and is suggested to be a result of a phenomenon known as acute tolerance (Ginsburg et al., 
2008). This develops rapidly after the consumption of alcohol, and the secondary effect is the 
sensation associated with intoxication and this decreases as the ethanol is eliminated. Studies in rats 
have verified this effect and a conclusion was drawn that proprioceptive response (the awareness of 
one’s own body parts) was less accurate with the rising of BAC than when BAC was declining (Wang 
et al., 1993). This could infer that a motorist that has undertaken driving while in the BAC absorption 
phase and prior to peak absorption may still have a degree of impairment even if they were under the 
prescribed 80 mg/dl legal limit. 
The development of alcohol addiction is attributed to a major system of the brain associated with 
reward and addiction known as the limbic system. This is the collection of areas of the brain associated 
with the release of reward related neurotransmitters such as dopamine, Gamma Amino Butyric Acid 
(GABA) and glutamate. This system is formed of several regions of the brain including the 
hippocampus which is associated with memory processing, the thalamus and hypothalamus which are 
linked to control of the endocrine system as well as body temperature regulation and feeding, while 
the amygdala and septum are the emotional centres (Leonard, 2005). This interconnected signalling 
nexus provides the necessary combination of reward related neurotransmitters, memory centres to 
reinforce the feelings and sights of the exposure to alcohol and the emotional centres to experience 
the mood-altering effects of ethanol. The reinforcement of behaviours such as consumption of alcohol 
in this case can be a major factor in a transition from casual or social ethanol consumption into full 
alcohol seeking behaviour and alcoholism. There are two types of reinforcing behaviour, a positive 
reinforcement which can be described as a rewarding stimulus such as the euphoria of ethanol 
consumption which can lead to alcohol seeking behaviours and a negative reinforcement behaviour 
which may be an aversive response in the case of alcohol this may be symptoms associated with 
withdrawal such as anxiety, aggression or dysphoria (Gilpin and Koob, 2008). Essentially an individual 
may exhibit alcohol seeking behaviours to avoid these unpleasant symptoms. 
Two key neurotransmitter receptors within the central nervous system (CNS) are affected by ethanol 
consumption and particularly by heavy and chronic drinking episodes. Alcohol is a known depressant 
and has an effect on the inhibitory neurotransmitter GABA. By binding to the GABAA receptor, it acts 
as an agonist for activity allowing an increased binding of GABA to the endogenous receptor. It also 
acts as an antagonist at NMDA (N methyl -D- Aspartate) type glutamate receptors which results in a 
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decreased responsiveness to released glutamate (Julien, 2011). The effect of the inhibited glutamate 
response alongside the enhanced GABA neurotransmission can lead to an adaptation response where 
there is an upregulation of NMDA receptors which results in excess glutamate release upon the 
removal of ethanol’s effects on GABA thus leading to withdrawal symptoms (Julien, 2011). The 
influence of ethanol on GABAA receptors also triggers a dysregulation of GABAergic transmission and 
this in turn stimulates an increase in activation of opioid receptors that result in an activation of 
dopaminergic reward neurons within the ventral tegmental area (VTA) (Julien, 2011), (Gilpin and 
Koob, 2008). This agonistic effect on GABAergic receptors is also believed to be linked to a positive 
reinforcement effect of ethanol (Julien, 2011). 
 
 
 
Table 1: Kurt Dubowski’s stages of acute alcoholic influence/ intoxication. Original BAC values were 
given in percent so a conversion into mg/dl was carried out for ease of interpretation of each stage 
(Dubowski, 1977). 
Table 1: Kurt Dubowski’s stages of acute alcoholic influence/intoxication 
Blood alcohol concentration (mg/dl) Stage of alcoholic influence Clinical signs/ symptoms 
10-50 Subclinical No apparent influence, behaviour will be observably normal. 
Changes may be detected with specialist tests. 
30-120 Euphoria Mild euphoria observable, talkative and sociable behaviours 
become notable, loss of inhibition or an increase in self-confidence, 
reduction in attention, judgement and control. A reduction in 
efficiency of fine performance tasks. 
90-250 Excitement Emotional instability further decreased inhibitions and critical 
judgement. Memory impairment may be observed with an increase 
in reaction time and incoordination will become apparent. 
180-300 Confusion Mental confusion/disorientation and dizziness, exaggerated 
emotional states such as anger, fear or grief, a decreased pain 
awareness following a general decrease in sensation slurred speech 
and impaired balance. 
270-400 Stupor Apathy, sensations of inertia. Approaching paralysis. Greater 
decrease in sensation to stimuli with a marked increase in muscular 
incoordination, resulting in an inability to stand or walk. Vomiting 
and urinary/faecal incontinence. Impaired consciousness resulting in 
sleep or stupor. 
350-500 Coma Complete loss of consciousness, anaesthesia or coma resulting in 
depressed or totally inhibited reflexes, subnormal body 
temperature, and urinary/faecal incontinence. Depressed rates of 
circulation and respiration resulting in possible death. 
450+ Death Death resulting from respiratory paralysis. 
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The role of ethanol in forensic toxicology 
 
In England and Wales, the legal blood ethanol limit for driving is currently set at 80mg/dl with a legal 
urine limit set at 107 mg/dl, in Scotland it is currently 50 mg/dl in blood and 67 mg/dl of urine. The 
breath limit in the UK is set at 35 μg/dl Drivers found to oversee a vehicle when over these limits are 
liable to be charged under section 5 of the Road Traffic Act 1988. This act states that a person is guilty 
of the offence of DUI (Driving whilst under the influence) if a person drives or attempts to drive a 
motor vehicle on a road or pubic place or is in charge of a motor vehicle on a road or public place after 
consuming so much alcohol that the blood, urine or breath level exceeds the prescribed limit.  Section 
7 of the act governs the provision of samples by a police officer and says that in the course of an 
investigation, a constable may require a specimen of blood urine or breath for a confirmatory test. 
But this sample may only be taken if the requirement is made at a hospital or police station. The 
requirement is imposed in circumstances where section 6 applies or the officer is in uniform. Failure 
to provide a sample is viewed in the same light as being above the per se limits. It should be noted 
that despite the limits in blood urine and breath being set at 80, 107 mg/dl and 35 μg/dl respectively, 
Gullberg (2012) cited the work of Wallis and Brownlie (1985) showing that an allowance for 
uncertainty of 6mg% or 6% is subtracted from the analytical value (Gullberg, 2012). Therefore, in 
practical terms for a blood or urine sample to be over the limit the analytical value must be 87mg% or 
113mg%.  By contrast the prosecution limit for breath is 40 micrograms per 100 ml of breath.  
 Two major studies led to the implementation of these limits. The first of these was carried out in 1964 
in a town in Illinois United States which later became known as the Grand Rapids by Professor 
Robert.F. Borkenstein, while the follow up carried out in 1994 in Germany by H.P Krueger et al. 
(Krueger et al. 1995) the purpose of both studies was to assess the risks of a driver being involved in 
an accident when blood alcohol concentration was factored in. The Grand Rapids study analysed and 
estimated alcohol in breath and blood of drivers involved in accidents. This was then compared to a 
large group of drivers passing the accident sites at the same time of day or on the same weekday, this 
group acted as the control group and their alcohol levels in breath and blood was plotted against those 
involved in accidents as a function of BAC (Lucas, 2000). 
The second study by Krueger et al. gave further evidence for a need to reduce the legal limit from 
80mg/dl to 50 mg/dl, the design of this study was like that of Borkenstein in that drivers were selected 
at the roadside by police who were following a random sampling plan (Krueger et al. 1995). At a 
separate checkpoint driver were randomly stopped, interviewed and asked for a breath sample, an 
accident study was also undertaken, and police were asked to take a breath sample from all accident 
drivers. This study took samples at a variety of times and days accounting for different times of the 
day and week where drinking may have been higher (Krueger, 1995). The risk factors of both studies 
were compiled into a graph by Krueger et al. to provide a comparison of the findings from both studies 
(Figure 4). The Borkenstein study suggested the implementation of a 100mg/dl BAC limit, this was 
later reduced in areas such as the UK to 80 mg/dl. The Krueger study highlighted that this was still too 
high however showing that at a BAC of 80mg/dl the risk factor of being involved in an accident was 
400 % higher (Lucas, 2000) than that of a driver that had no detectable alcohol in their system and 
some areas of the world responded to this and further reduced this to a limit of 50 mg/dl. 
 
12 
 
In the U.K. the road traffic act sets fixed limits on concentrations of intoxicating substances meaning 
a conviction will be incurred should a person be found to be driving with a higher concentration of a 
substance outlined within section 5 of this act. Given the effect that such a conviction can have on a 
person’s life it is vital that a method designed to detect these substances is robust, trustworthy and 
accurate to minimise the possibility of errors that can lead to wrongful convictions or acquittal. It is 
for this reason that forensic analytical methods are held to such a stringent standard and are so 
scrupulously examined during each stage of development and validation. With many aspects of the 
operation being checked, tested and refined including an external test scheme known as proficiency 
testing (PT) which is run by a wide variety of accredited practitioners and compares inter laboratory 
results obtained for a specified sample concentration. This highly controlled and regulated method 
development and validation process results in a high-quality method capable of detecting a wide 
variety of concentrations of either drugs or alcohol depending on the instrumentation used. For blood 
alcohol quantification, a method called GC-FID (Gas Chromatography with Flame Ionisation Detection) 
is frequently used. This is specialised technique for the detection volatile compounds such as alcohols. 
Given that alcohol is the most commonly used recreational drug worldwide, it is unsurprising that a 
common analytical test carried out within forensic toxicology is to determine the amount of ethanol 
in a person’s system. The analysis is typically carried out on blood and urine or vitreous humour, this 
type of analysis is used in variety of case types from drink/drug driving, drug facilitated sexual assault 
and deliberate and accidental drug overdoses. 
  
13 
 
 
 
 
 
 
 
 
Figure 4: The relative risk odds ratio plotted against the blood alcohol concentration. As demonstrated 
the risk factors of lower concentrations at 20 and 40 mg/dl (0.02 and 0.04 %) are approximately the 
same, however from 60 mg and above the risk factors were higher on average in the 1994 study by 
Krueger (Krueger et al., 1995). The grey line represents Borkenstein’s original data with the black line 
showing data from Krueger’s 1994 study. 
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Gas Chromatography with Flame Ionisation Detector 
 
A technique commonly applied within forensic laboratories for the analysis of alcohol in biological 
samples is gas chromatography (GC). This is often used in conjunction with a headspace auto sampler 
and flame ionisation detection (FID) (Mermet, 2004) which is referred to as headspace GC-FID. 
Headspace operates on the principle of Henry’s law, which states that the concentration ratio of a 
volatile substance in the gas phase of a vessel and the concentration in the liquid phase are fixed at a 
given pressure and temperature (Atkins, 2017). In the case of ethanol this means that the 
concentration of ethanol in the gas phase to be sampled is directly proportional to the concentration 
of ethanol found in the sample’s liquid phase. Headspace sampling has a major advantage over the 
alternative sample technique of direct liquid injection in that headspace is an extraction method along 
with the sampling method. A headspace sampler heats the sample vial to cause evaporation of the 
volatile components within the liquid phase resulting in the gas phase above the liquid, or the 
headspace, to reach an equilibrium with the liquid phase (Mermet, 2004). This headspace is then 
sampled by a syringe found within the auto-sampler, which is then injected into the inlet of the GC, 
and at this point it passes through the inlet and into the column where a separation of analytes occurs.  
GC columns come in two primary types, capillary and packed columns, dual capillary columns (utilising 
different polarities) are more commonly used in forensic blood alcohol analyses in modern analytical 
laboratories, however packed columns have been utilised in the past although they are rarely utilised 
today due to the improved overall performance of capillary columns (Holler, 2014), It is important for 
the dual columns to differ in polarity to ensure the separation properties are different. If both columns 
had identical separation properties it is a possibility that the presence of acetone for example would 
make an analysis of a sample very difficult.  
Capillary columns have a variety of applications ranging from biological fluid alcohol analysis to the 
analysis of accelerants in an arson case and some columns are more suited to specific applications 
than others. For example, the Restek BAC plus 1 and plus 2 columns chosen for this method are 
especially suited to the separation of alcohols due to the polarity, film thickness and internal diameter 
allowing for a short run time. The Fused silica used within a capillary column is relatively delicate and 
so columns are coated in a thin layer of polyimide to provide structural strength to the column, figure 
5 shows a cross sectional diagram of a capillary column. The stationary phase of a capillary column is 
an immobilised liquid which is coated to the walls of the column.  This liquid is highly viscous and 
specifically selected to have a boiling point of 100oC above the selected analysis temperature 
(Mermet, 2004). This coating can be done in two ways, the first is known as support coated open 
tubular (SCOT) which is pre-absorbed onto a porous support and the second coating is wall coated 
open tubular (WCOT) which, as the name suggests involves the liquid phase being thinly coated 
directly to the capillary wall (Mermet, 2004). In addition to the column, a mobile phase known as a 
carrier gas is used to carry the analytes along the column. Typically, in gas chromatography one of 
three gases, either helium, nitrogen or hydrogen is used (Rouessac, 2007). The optimum carrier gas to 
use for a method can be determined using the Van Deemter plot shown in figure 6, this is a measure 
of carrier gas efficiency, it should be noted that hydrogen gas is considered the most flexible gas to 
use as a carrier gas due to the wide range of optimum pressures when compared to helium and 
nitrogen, however helium is a safer alternative and is commonly utilised (Rouessac, 2007). 
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Figure 5: A cross section of a capillary GC column showing the protective outer coating made of 
polyimide, the fused silica base for the stationary phase and the stationary phase in which seperation 
occurs, the phase, internal diameter (ID) and film thickness will vary depending on the column type 
and the purpose of the column. These factors will affect the maximum capacity for a sample a column 
will have and also how analytes interact and separate on the column. 
 
Figure 6: The Van Deemter Plot showing that hydrogen has the widest range of linear velocities at 
which it will provide optimum efficiency with Nitrogen showing the narrowest range (Oden, 2015). 
 
Stationary phase 
Fused silica 
Polyimide coating 
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At the end of the separation process which takes place within the column the analytes must pass 
through a detector to be identified and the data transformed into a visual display, in the case of gas 
chromatography this would typically be a peak on a chromatogram. An internal standard is used as a 
reference and quantitation is achieved based on the ratio of the area of the analyte which has a varying 
concentration and the internal standard, which is the same concentration across all samples allowing 
for a calibration curve to be drawn (Rouessac, 2007). The flame ionisation detector is a highly sensitive 
detector type used in forensic blood alcohol analyses, the detetion limit is reported to be in the order 
of 2-3 pg/s and a linear range of 108 (Holler, 2014). Flame ionisation detectors (FID) are the most widely 
used type of detector for gas chromatography (Holler, 2014). FIDs operate on the gas flow from the 
column entering the detector space and being destroyed in a hydrogen flame, the resulting 
destruction of hydrocarbon compounds creates ions which are charged particles that pass through a 
weak current of around 10-12A (Amperes) between two electrodes, a ground potential that acts as a 
polarisation electrode and a collector electrode which surrounds the flame, the signal is amplified to 
a measureable voltage by an electrometer (Rouessac, 2007). It is believed Carbon atoms produce CH 
radicals within the flame which produce CHO+ ions and free electrons.  Flame ionisation detectors are 
sensitive to hydrocarbon compounds such as alcohols, but are insenstitive to compounds such as H2O, 
CO2, SO2 and NOX which can be advantageous if samples are diluted into water or contaminated with 
sulphate or nitrates as they are not detectable and so will not interfere with chromatograms (Holler, 
2014). 
Method development and validation 
 
The development of a method will be task specific, if a method has been developed for a specific 
customer purpose, the level of development and type of validation data may be different to a general 
purpose method, although all methods developed require some form of validation (Meyers, 2000). In 
a GC-FID method such as the method developed in this project, parameters are selected and optimised 
to the specified requirements of the analysis the method is developed to run. The specific 
requirements and validation experiments for this method are discussed below and demonstrate a 
validation plan for a specialist blood/urine alcohol detection method. Typically, validation of a method 
follows a similar pattern with the same parameters being verified. These parameters include but are 
not limited to; recovery, precision, accuracy, range, selectivity/specificity, limits of detection and 
working range. Potentially the most important of these parameters, and the parameters which should 
be monitored the most carefully are the reproducibility/repeatability and the accuracy (Higson, 2005). 
The components of validation are outlined and explained by Harris (Harris, 2010) in the quantitative 
chemical analysis providing an overview of each part of the process. The specificity of a method is the 
ability of the analytical method to distinguish analytes from one another, the ideal separation is known 
as baseline separation (Harris, 2010). Baseline separation, as the name suggests is the return to the 
baseline of one peak before signal of the next peak begins (Harris, 2010). The linearity of a method is 
a measure of how effectively a calibration curve follows a straight line, the calibration curve is formed 
from known standard concentrations and it is suggested by Harris that a linearity of between 0.995 
and 0.999 is considered adequate for most purposes (Harris, 2010).  
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The accuracy of a method is the closeness to the true value of a quantitation. A typical method of 
verification is the analysis of certified reference material (CRM), this method was used in the method 
developed in this research, a set is run after the calibration curve and a second is run after unknown 
samples verifying the accuracy of the analysis (Meyers, 2000). Meyers also notes that ISO guidelines 
define accuracy as a qualitative concept of the combination of precision and bias.  
Precision is defined by Harris as the measure of how well replicate measurements agree with one 
another, which is generally demonstrated by standard deviation,  Harris also suggested that there are 
more than one type of precision which are identified as; instrument or injection precision which is 
observed by injecting the same concentration of a sample a number of times (typically greater than 
or equal to ten separate times to monitor reproducibility and verifying the precision of the injection 
and instrumental variations (Harris, 2010) and intra-assay precision which is the analysis of  
homogenous aliquots several times in one day by a single analyst. It is expected that a higher variability 
will be expected due to the increased number of steps involved in this process (Harris, 2010).  
The next measures of precision also cover reproducibility, these are defined by Harris as intermediate 
precision and inter-laboratory precision, intermediate precision is the preparation of samples by more 
than one analyst on separate days (Harris, 2010). Inter-laboratory precision is very similar however 
the different analysts are running samples in different laboratories (Harris, 2010) and results between 
laboratories are then compared. 
The next factor of a validation is the range of the method. This is defined as the concentration interval 
at which precision, linearity and the accuracy are acceptable as per the specifications of the method 
(Harris, 2010). A reliable quantification can only be guaranteed within the calibration range, outside 
of these limits an accurate quantitation is no longer guaranteed, although it is still possible to achieve 
(Meyers, 2000). The final component of a typical validation is the limits of detection and quantitation, 
the limit of quantitation is the lowest concentration at which a quantitation can be achieved with a 
reasonable degree of accuracy (Harris, 2010), it is likely that this value will be the lowest calibrator 
used for the calibration curve given the calibration curve are the concentrations that are verified for 
accuracy.  
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Aims and method requirements 
 
The method was required to analyse and quantify the concentration of ethanol in both blood and 
urine to the standard of an ISO accredited laboratory. As this method utilised a dual column, dual 
detector configuration with one column acting as a primary column, and the second acting as the 
confirmatory column it is expected that both ethanol and tertiary butanol should elute with no 
interference on at least one of the columns, calibration curves should provide a linearity ( r2) of at least 
0.998 and are expected to be able to consistently quantify samples accurately and precision to a 
coefficient of variance (CV), also known as the relative uncertainty of no more than 2.5%. This method 
was developed and validated for commercial use according to an agreed validation plan. Upon 
validation, the method is intended for use with the analysis of road traffic act samples and the method 
will also be put forward for ISO accreditation. Prior to the validation process, the method was utilised 
to test the stability of blood, urine and LGC quality control samples in a room temperature stability 
test for up to one month and a two-cycle freeze thaw. 
 The objective of these studies was to investigate the effect of poor handling on sample stability. For 
example, the effect of unexpected breakdowns of a refrigerator and if samples are accidentally frozen 
in storage.  
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Materials and methods 
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Reagents and solvents 
 
The following reagents were used in the experimentation 
 Cerilliant ethanol standard solutions at concentrations of 10, 20, 50, 100, 200 and 400 
mg/100ml. 
 LGC European Reference Materials ethanol Certified Reference Material QC bottles at 
concentrations of 20, 80 and 200 mg/100ml. 
 Fisher scientific anhydrous tertiary butanol. 
 Fisher scientific sodium metabisulfite.  
 Propan-1-ol. 
 Propan-2-ol. 
 Methanol. 
 Acetaldehyde. 
 Acetone. 
 Distilled water. 
 Defibrinated horse blood. 
 Human blood (sourced in house from volunteers). Once opened this should be used 
within 30 days. 
 B sample human blood sourced an external accredited laboratory. 
Gases 
 Helium for use as carrier gas. 
 Hydrogen for use as FID fuel source. 
 Blank air for use as FID flame oxygen supply. 
 Nitrogen for use as a makeup gas. 
  Instrumentation and lab equipment 
 
Headspace Gas chromatogram with Flame Ionisation Detector 
 
 Shimadzu GC-2014 using a PC running Shimadzu GC solutions software with  BAC 1 and BAC 2 
dual column and FID -2014 configuration . 
 HTA 200 H headspace auto sampler utilising a gas tight syringe. 
 
Pipettes 
  Gilson P1000 1ml adjustable volume pipette.  
 Gilson 20-200 μl P200 adjustable volume pipette. 
 Gilson 2-20 μl P20 adjustable volume pipette. 
 Fixed volume 1ml pipette. 
 Gilson positive displacement pipette 10 -100 μl M100 adjustable volume. 
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Sample preparation 
Samples are prepared in duplicate using 100μl of analyte material in 1ml of internal standard in 
labelled 20ml headspace vials. The internal standard (ISTD) is prepared using 25 μl of tertiary butanol 
in 500 ml of distilled water; 2.5g of sodium metabisulfite antioxidant is also added. This solution is 
then inverted to homogenise the internal standard which can then be aliquoted into smaller bottles 
for easy storage. All samples should be prepared in a fume hood and in isolation of other solvents. 
Calibration curve standards are prepared by transferring 1ml of ISTD into 20ml headspace vials. 100 
μl of each standard concentration is then spiked within the vials; caps are then crimped on and 
checked for movement, properly crimped caps should not move. The same procedure applies to the 
quality controls, 1 ml of ISTD into each vial following 100 μl of each concentration these samples are 
now ready for analysis but can be stored overnight and analysed up to 24 hours later if required, one 
set of QCs will be run after the calibration curve to ensure the accuracy of the calibration is acceptable 
and the second set will be run after sample analysis to demonstrate that the accuracy of the analysis 
is acceptable.  
Headspace GC-FID procedure 
 
Prepared samples were placed into headspace sample carousel, and conditioned according to the 
headspace sampling parameters, the sampler then injected the sample volume into the SPL inlet and 
data acquisition will begin, a peak area and height will be added into the calibration curve post run of 
each sample for calibration standards. Upon completion of calibration standards a judgement can be 
made on linearity and accuracy after quality control samples run and report formats along with an 
ASCII format of numerical data can be generated post run. 
Uncertainty 
 
The uncertainty measurement used within the experimentation was the expanded uncertainty, this 
measurement accounts for the measurement uncertainty (also known as the standard deviation), the 
uncertainty of the quality controls used (20, 80 and 200 mg) and applies a confidence interval of 95%. 
The calculation of this variable follows the basic formula:  
 
Expanded uncertainty = √𝑆𝐷2 + 𝑢𝑛𝑐𝑒𝑟𝑡𝑎𝑖𝑛𝑡𝑦 𝑜𝑓 𝑡ℎ𝑒 𝑞𝑢𝑎𝑙𝑖𝑡𝑦 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑣𝑎𝑙𝑢𝑒 2 X the coverage factor 
(K) which in the experimentation was 2 or √𝑠𝑢𝑚 𝑜𝑓 𝑢𝑛𝑐𝑒𝑟𝑡𝑎𝑖𝑛𝑡𝑖𝑒𝑠2 X K.  
 
This provides the uncertainty of each set of quality control values calculated for a confidence interval 
of 95%. For biological samples, the standard deviation and Coefficient of variance (CV) also known as 
the relative uncertainty or relative standard deviation (Farrance, 2012) was used as measures of 
uncertainty as there is no unknown uncertainty attributed to samples making the expanded 
uncertainty unsuitable. 
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Instrument parameters 
 
GC method parameters 
Table 2: parameters for Gas chromatography analysis of ethanol 
Parameter Value 
Inlet Temperature (oC) 110 
Injection mode Split 
Pressure (Kpa) 85 
Column Flow (ml/min) 2.78 
Linear velocity (cm/sec) 42.30 
Purge flow (ml/min) 3.00 
Split ratio 5.00 
Oven temperature (oC) 40 isothermal 
Detector temperature(oC) 280 
Analysis time (minutes) 4 
 
Headspace sampling parameters 
Table 3: Headspace sampler parameters for analysis of ethanol 
Parameter Value 
Oven temperature (oC) 60 
Syringe temperature (oC) 70 
Fill volume (ml) 1.75 
Sample volume (ml) 1.00 
Incubation time (minutes) 5.00 
Shaker time (minutes ) 0.50 on 0.10 off 
Sample speed (ml/min) 5.0 
Injection speed (ml/min) 80 
 
Headspace GC-FID procedure 
 
Prepared samples were placed into headspace sample carousel, and conditioned according to the 
headspace sampling parameters, the sampler then injected the sample volume into the  inlet and data 
acquisition will begin, a peak area and height will be added into the calibration curve post run of each 
sample for calibration standards. Upon completion of calibration standards, a judgement can be made 
on linearity and accuracy after quality control samples run and report formats along with an ASCII 
format of numerical data can be generated post run. 
Uncertainty 
 
The uncertainty measurement used within the experimentation was the expanded uncertainty, this 
measurement accounts for the measurement uncertainty (also known as the standard deviation), the 
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uncertainty of the quality controls used (20, 80 and 200 mg) and applies a confidence interval of 95%. 
The calculation of this variable follows the basic formula:  
 
Expanded uncertainty = √𝑆𝐷2 + 𝑢𝑛𝑐𝑒𝑟𝑡𝑎𝑖𝑛𝑡𝑦 𝑜𝑓 𝑡ℎ𝑒 𝑞𝑢𝑎𝑙𝑖𝑡𝑦 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑣𝑎𝑙𝑢𝑒 2 X the coverage factor 
(K) which in the experimentation was 2 or √𝑠𝑢𝑚 𝑜𝑓 𝑢𝑛𝑐𝑒𝑟𝑡𝑎𝑖𝑛𝑡𝑖𝑒𝑠2 X K.  
 
This provides the uncertainty of each set of quality control values calculated for a confidence interval 
of 95%. For biological samples, the standard deviation and Coefficient of variance (CV) also known as 
the relative uncertainty or relative standard deviation (Farrance, 2012) was used as measure of 
uncertainty as there is no unknown uncertainty attributed to samples making the expanded 
uncertainty unsuitable. 
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Results 
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Method development 
 
Development began with initial selection of columns and internal standard; the column installed on 
the instrument upon first encountering the system was a single Phenomenex ZB-1 which had a film 
thickness of 25μm, a column length of 30.0m metres, and an inner diameter of 25mm and a maximum 
temperature of 360oC.  A dual column configuration was selected using RTX- BAC columns with the 
BAC plus-1 as the primary analysis column and the BAC plus-2 as the conformational secondary 
column, the reason for this was to provide two different separations based on different factors to 
identify any co-elution and prevent  peak interference with the target analyte or internal standard, 
ultimately  each column has a different retention time or elution order per analyte (McShane,  
2018).The first internal standard used was propan-2-ol, this however eluted too closely to ethanol 
with minimal baseline separation (Figure 17) meaning although there was no co-elution, it is a less 
suitable internal standard when compared to the other alternatives such as propan-1-ol and tertiary 
butanol. Propan-1-ol with the higher retention time allowed for a large separation between the two 
analytes, however the extended retention time made the method run time unnecessarily long, so 
tertiary butanol was selected as it provided the best balance of separation from ethanol whilst still 
allowing for a shorter total run time which increases efficiency and the turnover speed. All retention 
time values for ethanol and tertiary butanol were within the 2% identification window set within the 
analytical software.  
Parameter selection is a vital part of method development; it will dictate factors such as retention 
time, run time and the column lifetime. The main parameters selected for the method were GC oven 
temperature; pressure and conditioning time were adjusted to find the optimum balance of run time 
and separation. Selectivity was also tested at the early stages to determine how efficient the 
separation of common organic compounds encountered within a forensic analysis. 
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Column A peaks: 
1: Acetaldehyde 
2: Methanol 
3: Ethanol 
4: Acetone 
5: Isopropanol 
6: Tertiary 
Butanol 
7:1-propanol 
System suitability: 
The separation of a system suitability solution using the selected method parameters demonstrates 
the degree of separation that will be achieved between the components in the suitability solution. 
The suitability solution was prepared by adding 100 μl of methanol, acetaldehyde, acetone, 
isopropanol and 1-propanol analyte and 25 μl of tertiary butanol into a 1 litre bottle except for ethanol 
and homogenised. This system suitability solution was stored for use, this solution was diluted before 
use and 1ml was added to a 20 ml headspace vial, 100 μl of the 10 mg/dl Cerilliant standard ethanol 
was added at this point before the vial was sealed for analysis. 
 
 
Column A                                                                                  
 
 
 
 
 
 
 
 
 
 
 
 
1 
2 
3 
5 
6
7 
4 
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Figure 7: System suitability chromatogram demonstrating the selectivity of the method at the selected 
optimum pressure, conditioning time and oven temperature. Acetaldehyde co-elutes with methanol 
however the addition of sodium metabisulfite to the IS prevents its formation in casework samples. 
Column manufacturer material suggests a clear separation of all analytes; however, this uses 
unpractical conditions that would not be possible for accurate analytical quantitation. Retention time 
values for this analysis can be found in Table 11. 
Pressure optimisation 
Pressure optimisation was carried out based on a system suitability solution containing acetaldehyde, 
methanol, ethanol, acetone, isopropanol, tertiary butanol and propan-1-ol. Pressures were optimised 
by starting at 150kpa which decreased in 10 kpa increments until 90 kpa where an adjustment of only 
5 kpa was carried out and the optimum of 85 kpa was identified.  A test at a pressure below the 
identified optimum at 75 kpa was carried out to determine the effects of pressure on run time, peak 
shape and separation. It was determined that 85 kpa (Figure 9) provided the best run time whilst still 
having adequate separation on at least one column. As demonstrated, in figure 9 acetone co-elutes 
with ethanol and isopropanol on column A making samples with acetone difficult to quantify with this 
column. In the event of this occurrence it should be noted that acetone was detected in the sample 
and four samples should be prepared to obtain two sets of duplicate quantitative values with the 
second column with this being recorded in the data pack. It was also highlighted that lowering the 
pressure did not increase separation of acetone and ethanol on column A, the effect of the lower 
pressure was a relative retention time shift rather than the desired differential effect of separating 
ethanol and acetone. 
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Retention times at 150 kpa: 
Analyte Retention 
time column 
A (mins) 
Retention 
factor (K) 
Analyte Retention 
time column 
B (mins) 
Retention 
factor (K) 
Acetaldehyde 0.842 0.197 Methanol N/A N/A 
Methanol N/A N/A Acetaldehyde 1.022 0.353 
Ethanol 1.072 0.523 Ethanol 1.211 0.603 
Acetone 1.151 0.635 Isopropanol 1.468 0.943 
Isopropanol 1.214 0.725 Acetone 1.595 1.111 
Tertiary butanol 1.337 0.899 Tertiary butanol 1.732 1.293 
Propan-1-ol 1.692 1.404 Propan-1-ol 2.009 1.660 
Table 4: Retention time data of the 150 kpa pressure optimisation run. The retention times for most 
analytes are too close together and may cause issues with co-elution or quantitation making this 
pressure sub-optimal for the method. Methanol and acetaldehyde co-eluted to an extent where a 
retention time value for methanol not being available on both columns. 
Retention times at 140 kpa: 
Analyte Retention 
time column 
A (mins) 
Retention 
factor (K) 
Analyte Retention 
time column 
B (mins) 
Retention 
factor (K) 
Acetaldehyde 0.897 0.198 Methanol N/A N/A 
Methanol 0.951 0.270 Acetaldehyde 1.088 0.355 
Ethanol 1.141 0.524 Ethanol 1.290 0.606 
Acetone 1.226 0.637 Isopropanol 1.564 0.947 
Isopropanol 1.293 0.727 Acetone 1.699 1.116 
Tertiary butanol 1.424 0.901 Tertiary butanol 1.846 1.298 
Propan-1-ol 1.803 1.407 Propan-1-ol 2.141 1.666 
Table 5: Retention time data of the 140 kpa pressure optimisation run. The retention times for most 
analytes are too close together and may cause issues with co-elution or quantitation also making this 
pressure sub-optimal for the method. Methanol and acetaldehyde co-eluted to an extent where a 
retention time value for methanol not being available on column B. 
 
Retention times at 130 kpa: 
Analyte Retention 
time column 
A (mins) 
Retention 
factor (K) 
Analyte Retention 
time column 
B (mins) 
Retention 
factor (K) 
Acetaldehyde 0.959 0.198 Methanol N/A N/A 
Methanol 1.019 0.273 Acetaldehyde 1.165 0.356 
Ethanol 1.222 0.526 Ethanol 1.381 0.608 
Acetone 1.312 0.640 Isopropanol 1.165 0.950 
Isopropanol 1.385 0.730 Acetone 1.819 1.119 
Tertiary butanol 1.525 0.905 Tertiary butanol 1.977 1.302 
Propan-1-ol 1.931 1.412 Propan-1-ol 2.293 1.671 
Table 6: Retention time data for the 130 kpa optimisation run, at this pressure the run time is still low, 
and peaks are still eluting too closely for analysis to eliminate coelutions. 
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Retention times at 120 kpa: 
Analyte Retention 
time column 
A (mins) 
Retention 
factor (K) 
Analyte Retention 
time column 
B (mins) 
Retention 
factor (K) 
Acetaldehyde 1.030 0.196 Methanol 1.188 0.285 
Methanol 1.098 0.275 Acetaldehyde 1.254 0.356 
Ethanol 1.316 0.528 Ethanol 1.487 0.609 
Acetone 1.413 0.641 Isopropanol 1.804 0.951 
Isopropanol 1.492 0.732 Acetone 1.960 1.120 
Tertiary butanol 1.643 0.907 Tertiary butanol 2.130 1.304 
Propan-1-ol 2.080 1.415 Propan-1-ol 2.471 1.673 
Table 7: Retention time data for the 120kpa optimisation run, at this pressure the run time is still low, 
and peaks are still eluting too closely for analysis to eliminate co-elution. 
Retention times at 110 kpa: 
Analyte Retention 
time column 
A (mins) 
Retention 
factor (K) 
Analyte Retention 
time column 
B (mins) 
Retention 
factor (K) 
Acetaldehyde 1.115 0.195 Methanol 1.285 0.288 
Methanol 1.188 0.273 Acetaldehyde 1.356 0.359 
Ethanol 1.425 0.528 Ethanol 1.610 0.613 
Acetone 1.531 0.641 Isopropanol 1.955 0.959 
Isopropanol 1.616 0.732 Acetone 2.124 1.129 
Tertiary butanol 1.780 0.908 Tertiary butanol 2.310 1.314 
Propan-1-ol 2.254 1.417 Propan-1-ol 2.680 1.686 
Table 8: Retention time data for the 110 kpa optimisation run demonstrating a further shift when 
compared to 120 kpa. 
Retention times at 100 kpa: 
Analyte Retention 
time column 
A (mins) 
Retention 
factor (K) 
Analyte Retention 
time column 
B (mins) 
Retention 
factor (K) 
Acetaldehyde 1.215 0.196 Methanol 1.404 0.287 
Methanol 1.296 0.276 Acetaldehyde 1.483 0.359 
Ethanol 1.556 0.532 Ethanol 1.760 0.613 
Acetone 1.671 0.645 Isopropanol 2.137 0.959 
Isopropanol 1.765 0.737 Acetone 2.323 1.129 
Tertiary butanol 1.944 0.914 Tertiary butanol 2.525 1.314 
Propan-1-ol 2.464 1.426 Propan-1-ol 2.931 1.686 
Table 9: Retention time data for the 100 kpa optimisation run demonstrating a further shift in 
retention times. 
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Retention times at 90 kpa: 
Analyte Retention 
time column 
A (mins) 
Retention 
factor (K) 
Analyte Retention 
time column 
B (mins) 
Retention 
factor (K) 
Acetaldehyde 1.345 0.199 Methanol 1.552 0.285 
Methanol 1.430 0.275 Acetaldehyde 1.640 0.357 
Ethanol 1.717 0.531 Ethanol 1.946 0.611 
Acetone 1.846 0.645 Isopropanol 2.362 0.955 
Isopropanol 1.949 0.737 Acetone 2.567 1.125 
Tertiary butanol 2.147 0.914 Tertiary butanol 2.791 1.310 
Propan-1-ol 2.722 1.427 Propan-1-ol 3.239 1.681 
Table 10: Retention time data for the 90 kpa optimisation run demonstrating a further shift in 
retention times and a slight increase in separation of analytes. 
Retention times at 85 kpa: 
Analyte Retention 
time column 
A (mins) 
Retention 
factor (K) 
Analyte Retention 
time column 
B (mins) 
Retention 
factor (K) 
Acetaldehyde 1.419 0.200 Methanol 1.637 0.290 
Methanol 1.509 0.276 Acetaldehyde 1.729 0.362 
Ethanol 1.813 0.533 Ethanol 2.053 0.618 
Acetone 1.948 0.647 Isopropanol 2.493 0.964 
Isopropanol 2.057 0.739 Acetone 2.709 1.135 
Tertiary butanol 2.266 0.916 Tertiary butanol 2.945 1.321 
Propan-1-ol 2.874 1.429 Propan-1-ol 3.419 1.694 
Table 11: Retention time data for the 85 kpa optimisation run demonstrating a further shift in 
retention times and a slight increase in separation of analytes. This was determined as the optimum 
pressure. 
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Column peaks: 
1: Acetaldehyde 
2: Methanol 
3: Ethanol 
4: Acetone 
5: Isopropanol 
6: Tertiary 
Butanol 
7:1-propanol 
85 kpa:  
Column A                                                                                  
 
 
 
 
` 
 
 
 
 
 
 
 
 
Figure 9:  Chromatographic display for 85 kpa, despite an improvement in separation and an increased 
run time. This pressure was determined as the optimum for separation of key analytes (ethanol and 
tertiary butanol) whilst maintaining a relatively short retention time. 
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Retention times at 75 kpa: 
Analyte Retention 
time column 
A (mins) 
Retention 
factor (K) 
Analyte Retention 
time column 
B (mins) 
Retention 
factor (K) 
Acetaldehyde 1.590 0.198 Methanol 1.830 0.292 
Methanol 1.696 0.278 Acetaldehyde 1.933 0.365 
Ethanol 2.040 0.537 Ethanol 2.300 0.624 
Acetone 2.191 0.651 Isopropanol 2.802 0.979 
Isopropanol 2.314 0.744 Acetone 3.046 1.151 
Tertiary butanol 2.551 0.922 Tertiary butanol 3.315 1.341 
Propan-1-ol 3.235 1.438 Propan-1-ol 3.848 1.717 
Table 12: Retention time data for the 75 kpa optimisation run demonstrating a further shift in 
retention times and a slight increase in separation of analytes. 
 
Temperature selection  
Temperature optimisation for this method was also carried out to determine if a higher temperature 
of 45 oC would improve the separation of analytes such as acetone on column A, as shown in figure 10 
the peaks eluted even more closely resulting in a full co-elution, whilst not providing any improvement 
in separation of ethanol and acetone. The optimum temperature was 40 oC and this was selected for 
the method, pressure adjustment was also attempted to enhance the temperature selection to 
achieve the separation and run time balance. 
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Column peaks: 
1: Acetaldehyde 
2: Methanol 
3: Ethanol 
4: Acetone 
5: Isopropanol 
6: Tertiary 
Butanol 
7:1-propanol 
40 oC 
Column A                                                                               
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Column B 
 
Figure 10: Chromatographic display of 40 oC GC oven conditions, this temperature was selected as the 
optimum allowing separation of key analytes (ethanol and tertiary butanol) whilst also allowing a 
moderately short run time. 
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Column peaks: 
1: Acetaldehyde 
2: Ethanol 
3: Acetone 
4: Isopropanol 
5: Tertiary 
Butanol 
6:1-propanol 
45 oC 
Column A                                                                              
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Column B 
 
Figure 11: Chromatographic display of 45 oC GC oven temperature, column A shows an increased co-
elution of methanol and acetaldehyde suggesting a differential change in retention times of analytes, 
the same is displayed in acetone and isopropanol, separation of acetone and ethanol does not appear 
to have improved when compared to 40 oC.  
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Conditioning time 
Headspace conditioning time was assessed to review the impact of conditioning time on peak 
responses and to determine if there was a significant increase in peak area and height observed in 
samples conditioned for longer. Times of 5, 10, 15 and 20 minutes were selected, and a quantitation 
of the observed concentration was taken to determine if an increase in conditioning time contributed 
to an increase in quantitative value. The peak areas did not increase significantly according to the 
quantitation data with under a 1mg difference between a 5 and 20-minute conditioning time thus a 
5-minute conditioning time was selected.  
Table 13: Quantitative data demonstrating the quantification of the QC 20 at a 5,10,15 and 20-minute 
conditioning time. 
 
 
 
 
 
 
 
 
 
 
Table 13: Conditioning time summary data 
 Concentration mg/dl % difference from 
expected 20 mg/dl 
Peak area Peak height 
 Column A Column B Column 
A 
Column 
B 
Column A Column B Column A Column B 
5 minutes  
Ethanol 21.33 20.46 106.65 102.30 9880 11538 3139 2776 
Tertiary Butanol 0.000 0.000 N/A N/A 95958 113025 31005 25701 
10 minutes  
Ethanol 21.36 21.15 106.80 105.75 10541 12750.3 3410 3035.2 
Tertiary Butanol 0.000 0.000 N/A N/A 102238 120607 32989 27561 
15 minutes  
Ethanol 21.39 21.15 106.95 105.75 10165 12289 3303 2937 
Tertiary Butanol 0.000 0.000 N/A N/A 98433 116248 31793 26551 
20 minutes  
Ethanol 21.40 20.91 107.00 104.55 10765 12802 3496 3092 
Tertiary Butanol 0.000 0.000 N/A N/A 104210 122566 33678 27909 
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5 minutes 
Column A                                                                             Column B    
 
Figure 12: Chromatographic display for the 5-minute conditioning time. Peak 1 represents ethanol 
with peak 2 representing the internal standard tertiary butanol. 
10 minutes 
Column A                                                                             Column B    
 
Figure 13: Chromatographic display for the 10-minute conditioning time. Peak 1 represents ethanol 
with peak 2 representing the internal standard tertiary butanol. 
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15 minutes 
Column A                                                                             Column B 
 
Figure 14: Chromatographic display for the 15-minute conditioning time. Peak 1 represents ethanol 
with peak 2 representing the internal standard tertiary butanol. 
20 minutes 
Column A                                                                             Column B 
 
Figure 15: Chromatographic display for the 20-minute conditioning time. Peak 1 represents ethanol 
with peak 2 representing the internal standard tertiary butanol. 
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Optimum conditions 
The optimum parameters selected for this method were 40oC GC oven temperature, a 5-minute 
conditioning time and an 85kpa pressure (Table 17). These parameters allowed for the best balance 
of run time separation and response, while there may have been better conditions for separation or 
run time individually, these conditions provided the best for both parameters. As demonstrated in the 
system suitability solution, acetaldehyde and methanol co-elute on both columns. The addition of an 
antioxidant, sodium metabisulfite in the internal standard solution prevents the build-up of 
acetaldehyde in analytical samples, methanol is also not typically analysed in road traffic blood alcohol 
analyses, so this co-elution is not anticipated to cause any issues with this method. 
Table 17: Selected method parameters 
Parameter: Optimum selected 
Conditioning time 5 minutes 
Oven temperature 40oC 
Pressure 85kpa 
Table 14: Demonstrating the selected optimum parameters used for the method 
Separation of ethanol and internal standard using selected conditions: 
Column A                                                                                 
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Column B    
 
Figure 16: A chromatographic display demonstrating acceptable separation of ethanol and tertiary 
butanol, the internal standard on both columns. Peak 1 represents ethanol with peak 2 representing 
the internal standard tertiary butanol. 
Acetone co-elution 
A sample of ethanol spiked with acetone was analysed to determine the impact of co-elution on 
ethanol in isolation. Figure 18 demonstrates the degree of separation on column B which shows that 
it can be used to quantify ethanol without interference should acetone be detected in a sample. In 
the case of a low concentration of acetone it may not interfere with ethanol, however it is generally 
an interfering peak that results in interference on column A.  A detection of a high amount of acetone 
usually results in a disparity of quantitation of ethanol between column A and column B and it will be 
clear that acetone has interfered with the quantitation, the amount of acetone required to interfere 
with an analysis is unknown, however a relatively low amount has the potential to interfere with the 
integrated peak area of ethanol effecting the quantitation. The purpose of this analysis was to 
demonstrate that acetone will elute closely with ethanol on one column in the absence of any other 
potential interferences including an internal standard. For this reason, a quantitation of ethanol was 
not achieved. 
 
1 
2 
42 
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Column B    
 
Figure 18: A chromatographic display of acetone and ethanol co-elution. Full separation is achieved 
with column B; however, baseline separation is not achieved on column A which will in some cases 
cause distortion of quantitative values obtained. For this reason, samples with acetone present are 
quantified on B column alone. Peak 1 represents ethanol with peak 2 representing the acetone. 
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Linearity 
The linearity is automatically calculated by the GC software from the calibration curve created using a 
total of six calibration points, that is six separate concentrations ranging from 10 to 400mg/ using 
concentrations of 10,20,50,100,200 and 400 mg/dl. This value is represented as an r2 value and the 
closer to a value of 1 this value is, the better the linearity. As demonstrated in figures, 19, 19.1 and 
table 20 linearity for this method was well in excess of the pass criteria featured in table 26 suggesting 
that the method accuracy and pipetting of samples was above the standard required of an analyst and 
analytical method. Samples of a concentration above 400 are analysed however the accuracy of the 
quantitation cannot be guaranteed. 
Figure 19: Representative calibration curve for column A  shown in  table15 . Concentrations of 10, 
20, 50,100,200 and 400 mg/dl were used to calibrate the instrument, each calibration level was run in 
duplicate. 
 
 
 
 
 
 
Table 15: The summary data given in the calibration curve table generated in figure 19.  The attained 
areas of each calibrator are included demonstrating the pattern of the increasing peak area with 
increasing concentration.     
Level Concentration 
(mg/dl) 
Mean area 
ratio 
Standard 
deviation 
Relative 
standard 
deviation 
(%) 
Area 1 Area 2 
1 10 0.04 3.31 0.80 7,214 7,024 
2 20 0.08 6.29 0.75 14,395 14,571 
3 50 0.23 6.14 2.73 38,956 37,250 
4 100 0.45 6.57 1.46 76,337 75,637 
5 200 0.88 3.95 4.48 149,434 152,200 
6 400 1.71 3.18 1.85 304,440 252,372 
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Figure 19.1: Representative calibration curve demonstrating a typical display for column B curves 
shown in table 16. Concentrations of 10, 20, 50,100,200 and 400 mg/dl were used to calibrate the 
instrument, each calibration level is run in duplicate. 
Level Concentration 
(mg/dl) 
Mean area 
ratio 
Standard 
deviation 
Relative 
standard 
deviation 
(%) 
Area 1 Area 2 
1 10 0.04 2.02 0.47 5,712 5,610 
2 20 0.09 2.99 0.34 11,253 11,338 
3 50 0.23 5.62 2.46 30,035 28,883 
4 100 0.46 6.03 1.32 58,954 58,560 
5 200 0.90 3.28 3.64 115,661 117,791 
6 400 1.82 3.37 1.84 234,821 201,862 
Table 16: The summary data given in the calibration curve table generated in figure 19.1.  The attained 
areas of each calibrator are included demonstrating the pattern of the increasing peak area with 
increasing concentration.     
Table 20: Linearity data at the method development stage 
Date acquired Linearity Column A Linearity Column B 
01/03/2018 0.9997 0.9997 
04/03/2018 0.9996 0.9998 
06/03/2018 0.9996 0.9999 
28/03/2018 0.9999 0.9999 
12/04/2018 0.9998 0.9998 
24/04/2018 0.9997 0.9997 
Average 0.9997 0.9998 
Table 17: Linearity values for calibration curves of batches from the method development stage picked 
at random for inclusion, the data demonstrates that linearity at this stage was well in excess of the 
pass limit for the method linearity (0.998). (Linearity values shown in figure 19 and 19.1 are highlighted 
in bold). 
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Accuracy and precision 
The accuracy and precision were recorded in quality control charts generated in Microsoft excel (figure 
20, 20.1 and 20.2) which were prepared by using the mean as the centre line, the mean plus 3 and 
minus 3 standard deviations represents the control limits and plus or minus two standard deviations 
for the warning limits. Averages of QC results from batches were plotted, if a point exceeds the control 
limits then this should be assessed, and a possible cause determined as well as whether action should 
be taken to prevent these occurrences. If more than one point exceeds the warning limits it may 
suggest an issue which could need to be addressed however this may not be required if it is one point. 
A pattern of more than 4 increasing points or decreasing points consecutively may also be an 
indication of either an analyst skill issue or an issue with reliability of the method. At the method 
development stage only one set of QCs were used per batch compared to the later validation batches 
which have a set post calibration curve and a second post samples, providing two average values per 
concentration. It is for this reason that only half the number of points are used demonstrating the 
accuracy of the method over the same number of batches. Although there were more values available 
to add, the charts are representative of the precision and accuracy at the early stages of method 
development.  
 
 
 
Figure 20: QC chart demonstrating precision of the low concentration quality control, all values were 
within 2 standard deviations of the mean showing that no corrective action was required with the 
method.  
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Figure 20.1: QC chart for the mid concentration quality control, this chart shows a similar pattern to 
the low concentration calibrator. 
 
 
 
 
Figure 20.2: QC chart for the highest Quality control concentration, of the three concentrations the 
high concentration is shown to demonstrate the greatest accuracy.  
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 Troubleshooting 
During the method development the installation of the new BAC 1 plus and BAC 2 plus columns the 
insertion of the columns into the split was unequal, this is highlighted in the featured batch showing 
a large discrepancy between the column A and column B quantitation. This was rectified by removing 
the columns, verifying the lengths of each column and correcting the insert lengths before cutting and 
reinstalling the column at the splitter.  
QC 20  
Column A                                                                             Column B    
 
Figure 21: Chromatographic display of the failed batch QC 20 data. Peak 1 represents ethanol with 
peak 2 representing the internal standard tertiary butanol. 
QC20 mg/dl Concentration mg/dl Retention time Peak area Peak height 
Analyte Column A Column B Column A Column B Column A Column B Column A Column B 
Ethanol 19.648 39.066 1.918 2.088 11231 9143 2167 1909 
Tertiary Butanol 0.000 0.000 2.393 2.988 278416 220781 53564 44667 
Table 18: Quantitative data for the failed batch showing the discrepancy between column A and 
column B concentration. 
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QC 80  
Column A                                                                             Column B    
                                                            
Figure 22: Chromatographic display of the failed batch QC 80 data Peak 1 represents ethanol and peak 
2 the internal standard tertiary butanol. 
QC 80 mg/dl Concentration mg/dl Retention time Peak area Peak height 
Analyte Column A Column B Column A Column B Column A Column B Column A Column B 
Ethanol 79.670 154.807 1.920 2.088 45643 36749 8914 7756 
Tertiary Butanol 0.000 0.000 2.395 2.987 273512 216904 52977 43953 
Table 19: Quantitative data for the failed batch showing the discrepancy between column A and 
column B concentration. 
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QC 200 
Column A                                                                            Column B    
 
Figure 23: Chromatographic display of the failed batch QC 200 data Peak 1 represents ethanol and 
peak 2 the internal standard tertiary butanol. 
QC 200 mg/dl Concentration mg/dl Retention time Peak area Peak height 
Analyte Column A Column B Column A Column B Column A Column B Column A Column B 
Ethanol 197.749 383.799 1.914 2.806 121260 97796 23697 20595 
Tertiary Butanol 0.000 0.000 2.391 2.987 291625 231363 56221 46669 
Table 20: Quantitative data for the failed batch showing the discrepancy between column A and 
column B concentration. 
 
 
 Table 21: The summary of the failed batch data demonstrating the differences in column A and 
column B quantitation.  
 
 
 
 
Table 24: Summary of failed batch results 
 Concentration mg/dl Expected 
concentration 
mg/dl 
Retention time Peak area Peak height 
Analyte Column A Column B  Column A Column B Column A Column B Column A Column B 
Ethanol 19.648 39.066 20 1.918 2.088 11231 9143 2167 1909 
Tertiary Butanol 0.000 0.000 0 2.393 2.988 278416 220781 53564 44667 
Ethanol 79.670 154.807 80 1.920 2.088 45643 36749 8914 7756 
Tertiary Butanol 0.000 0.000 0 2.395 2.987 273512 216904 52977 43953 
Ethanol 197.749 383.799 200 1.914 2.806 121260 97796 23697 20595 
Tertiary Butanol 0.000 0.000 0 2.391 2.987 291625 231363 56221 46669 
1 1 
2 2 
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Quantitation of an unknown sample 
A horse blood sample was run to demonstrate the accuracy of the instrumentation in detecting an 
unknown concentration of ethanol in a blood sample, the spiked amount was 20 mg/dl and the 
instrument demonstrated the ability to detect and quantify the unknown samples in blood, suggesting 
good accuracy within the stated limits. 
Blood sample 
Column A                                                               Column B                  
 
Figure 24: Chromatogram display demonstrating separation of analytes and clear peak shape in a 
blood sample. Peak 1 represents ethanol with peak 2 representing the internal standard tertiary 
butanol. 
 Concentration mg/dl Expected 
concentration 
mg/dl 
Retention time Peak area Peak height 
Analyte Column A Column B  Column A Column B Column A Column B Column A Column B 
Ethanol 18.687 18.849 20 1.883 2.055 10372 7426 2602 2208 
Tertiary Butanol 0.000 0.000 0 2.351 2.954 138209 95961 34912 25760 
Table 22: A sample of 20 mg/dl was spiked into 1 ml of internal standard for analysis to verify the 
system’s capability of quantifying true unknowns, it was also done to determine the suitability of the 
instrument to analyse blood samples. Quantitation was within the ± 2mg limit of the expected 20 
mg/dl in both columns demonstrating good accuracy of quantitation in a blood sample. 
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Method validation criteria: 
Validation plan: 
Validation 
experiment 
Experimentation 
required 
Pass criteria Attained performance Result 
LOD Three samples of 
blood spiked at 
5mg/dl using 50 
μl of Cerilliant 
standard 10 
mg/dl will be run 
to verify 
detection was 
achieved. 
Detection of all 
three samples with 
clean integrated 
peaks and a signal –
noise ratio of 
greater than 3:1 or 
appear as a clean 
peak on visual 
inspection. 
Clear peaks were seen 
on all samples and both 
columns. The LOD for 
ethanol is 5 mg/dl. 
PASS 
LOQ 100 μl of 
Cerilliant 
standard 100 
mg/dl will be 
diluted into 1 ml 
of internal 
standard in 
duplicate. 
Samples should 
provide a reading 
within 2 mg of the 
expected 10 mg/dl 
concentration. 
All observed 
concentration values 
were within 2mg of the 
10 mg/dl expected 
concentration 
PASS 
Linearity Linearity will be 
demonstrated 
within calibration 
curve data on 
each calibration 
curve produced. 
The minimum 
linearity r2 value will 
be 0.998. 
All r2 values in the 
validation exceeded 
0.998. 
PASS 
Range The range of the 
method is 10-
400mg mg/dl. 
Quality control 
samples at 20, 80 
and 200mg/dl 
demonstrating 
precision within 
the curve limits. 
Quality control 
samples should have 
no more than two 
points which fall 
outside of the 
control limit of the 
mean ± 3 standard 
deviations and no 
more than 4 points 
outside of the 
warning limits± 2 
standard deviations. 
All Qc values featured in 
Quality control charts 
fell within 2 standard 
deviations of the mean. 
PASS 
Repeatability 
 
 
 
 
 
 
 
 
 
A single analyst 
will prepare and 
run batches on 
three separate 
occasions on the 
same instrument. 
The batches will 
contain a 
standard curve 
featuring 6 
All replicates for 
each Qc should fall 
within a 2.5% CV 
and within 2mg for 
20 mg/dl and 80 
mg/dl and 6 mg for 
200mg. 
All QC values were 
within the 2.5% CV, all 
values were within 2mg 
of the expected values 
with the exception of 
one 
PASS 
53 
 
Repeatability 
continued 
concentrations 
(10-400mg/dl) 
and two sets of 
QCs. QC samples 
will determine 
whether the 
batches were 
successful. 
Reproducibility 3 batches will be 
prepared by 3 
different analysts 
on separate days 
and run on the 
same instrument. 
Each batch will 
contain the 
standard 6-point 
calibration curve 
with two sets of 
duplicate QCs (6 
aliquots). 
All replicates for 
each Qc should fall 
within a 2.5% CV 
and within 2mg for 
20 mg/dl and 80 
mg/dl and 6 mg for 
200mg. 
Qc values were within 
the 2mg/dl limit for QC 
20 and 80 mg/dl and 6 
mg of the 200 mg/dl. 
 
PASS 
Accuracy Accuracy will be 
assessed with QC 
results obtained. 
There should be no 
significant bias 
within samples, QC 
values should be 
within 2mg for QC 
20 and 80 and 6 mg 
for QC 200mg. 
Qc values were within 2 
mg of the QC 20 and QC 
80 and within 6mg of 
the QC 200 mg/dl. 
PASS 
Selectivity Solutions of 
Acetaldehyde, 
methanol, 
ethanol, acetone, 
tertiary Butanol, 
propan-1-ol and 
propan-2-ol, first 
as single runs to 
determine 
retention order 
then as a mix to 
determine 
separation. 
Baseline separation 
should be achieved 
between the 
primary analyte 
(ethanol) and all 
other selectivity 
components on at 
least one column. 
Baseline separation of 
primary analyte and all 
other potential 
interfering peaks was 
achieved on at least one 
column. 
PASS 
Table 23: Validation outline indicating parameters for a successful validation, experimentation 
required to test the method and a judgement on if the method meets the requirements. 
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Limit of detection 
Samples for limit of detection testing were prepared at 5mg/100ml using 50 μl of the 10mg/100ml 
Cerilliant standard in 1ml of ISTD. Although quantitative values were generated (Table 27) the values 
were outside the calibration curve and therefore accuracy of the quantitation cannot be assured. 
However according to the international conference on harmonisation (ICH) guidelines, it is plausible 
to determine detection limit by visual evaluation. The guideline for this approach is that limit of 
detection determined by an analysis of known concentrations of an analyte and establishing the 
minimum level with which the analyte can be reliably detected (ich.org, 2005). In this case 5 mg was 
selected and as demonstrated a relative degree of reliability of the quantitation was achieved and for 
this reason this method was used.  
 
Figure 24: Chromatographic display of LOD experimentation demonstrating peak shape at 5mg/dl.  
Table 25: Quantitative data for LOD experimentation. 5 mg/dl is below the lowest calibrator (10mg/dl) 
and so accuracy cannot be guaranteed.  LOD judgement was based on the appearance of a clean 
integrated peak. 
 
 
 
Expected 
concentration 
(mg/dl) 
Observed 
concentration 
(mg/dl) 
Peak area Peak height Matrix 
5 6.4175 2261 606 Blood 
5 6.2545 2052 556 Blood 
5 5.9945 2205 595.5 Water 
5 5.8995 2133 580 Water 
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Limit of quantitation 
The limit of quantitation (LOQ) was the lowest concentration that can be accurately 
quantified, in the case of this method the lowest calibrator was 10mg/dl, this means that 
10mg/dl is the lowest concentration of ethanol that can be accurately quantified and as such 
it was selected as the LOQ for the method. The samples were prepared as standard using the 
procedure for preparing the 10 mg/dl calibrator, the LOQ was run in triplicate to confirm an 
accurate quantitation. 
Table 26: LOQ observed concentrations are averages of column A and B for each value. 
 
Linearity, accuracy and precision of method validation 
Linearity data attained at the method validation stage 
Date acquired Linearity Column A Linearity Column B 
19/06/2018 0.9999 0.9999 
20/06/2018 0.9999 0.9999 
26/06/2018 0.9999 0.9999 
28/06/2018 0.9999 0.9999 
05/07/2018 0.9997 0.9997 
11/07/2018 0.9999 0.9999 
Average 0.9999 0.9999 
Table 27: Linearity of calibration curves from different analyses. The target minimal accepted R2 value 
was 0.998, the method demonstrated a consistently higher linearity than this target with a typical 
value being 0.9999. Values from the representative calibration curve in figure 26 are highlighted in 
bold. 
 
 
 
 
 
Table 28: Limit of quantitation  
Sample number Expected 
concentration 
(mg/dl) 
Column A 
concentration 
(mg/dl) 
Column B 
concentration 
(mg/dl) 
Average 
observed 
concentration 
(mg/dl) 
%Accuracy 
10 mg sample 1 
 
10 10.79 10.89 10.84 108.39 
10 mg sample 2 
 
10 10.77 
 
10.91 
 
10.84 108.41 
10 mg sample 3 10 10.85 
 
10.85 
 
10.85 108.53 
 Average 10.80 10.84 10.84 108.44 
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Representative linearity calibration curve 
Column A 
 
 
 
 Figure 26: Representative calibration curve display for Column A data shown in Table 28, showing R2 
values, along with response ratios used to calculate concentration. Calibration curves are made up of 
6 concentrations at 10, 20, 50,100,200 and 400mg/dl using a set of duplicates for each concentration. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 38: The summary data given in the calibration curve table generated in figure 26.  The attained 
areas of each calibrator are included demonstrating the pattern of the increasing peak area with 
increasing concentration.    
 
 
 
 
 
 
 
 
 
 
 
 
Level Concentration 
(mg/dl) 
Mean area 
ratio 
Standard 
deviation 
Relative 
standard 
deviation 
(%) 
Area 1 Area 2 
1 10 0.03 7.46 2.40 5,969 5,730 
2 20 0.06 5.52 0.92 10,914 11,100 
3 50 0.16 1.81 1.16 28,331 29,384 
4 100 0.32 3.06 0.96 59,720 57,889 
5 200 0.65 1.40 0.22 120,593 122,470 
6 400 1.31 3.59 0.27 244,187 232,538 
 
57 
 
 
 
Column B 
 
 
Figure 26.1: Typical calibration curve display for Column B data shown in Table 29, showing R2 values, 
along with ratios used to calculate concentration. Calibration curves are made up of 6 concentrations 
at 10, 20, 50,100,200 and 400mg/dl using a set of duplicates for each concentration. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 29: The summary data given in the calibration curve table generated in figure 26.1.  The 
attained areas of each calibrator are included demonstrating the pattern of the increasing peak area 
with increasing concentration.     
 
 
 
 
 
 
 
 
 
 
 
 
Level Concentration 
(mg/dl) 
Mean area 
ratio 
Standard 
deviation 
Relative 
standard 
deviation 
(%) 
Area 1 Area 2 
1 10 0.03 2.26 0.68 4,517 4,278 
2 20 0.06 5.90 0.93 8,008 7,931 
3 50 0.16 2.40 1.48 20,156 20,990 
4 100 0.33 2.51 0.76 42,211 40,882 
5 200 0.67 1.84 0.28 85,339 86,882 
6 400 1.14 6.45 0.48 171,623 164,076 
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Range 
 
The range of the quality control values is a measure of how precise the quantitation is over an 
extended period; a quality control chart is used to verify this. From the chart, control limits were set 
to provide the maximum and minimum acceptable value for the method standard deviation and 
means, the control limits are set at the mean ± 3 standard deviations. Warning limits are similar 
however use a value of the mean ± two standard deviations. Results outside of these limits warrant 
further investigation. however, a decision in what action if any is to be taken. Figure 27, 27.1 and 27.2 
demonstrate that in the analyses demonstrated a good inter-run accuracy and precision. Gross errors 
are not included within the charts. A set of 5 validation batches were selected for each chart to provide 
a representation of the accuracy of the method during the validation process and to provide a 
proportional comparison of the accuracy of 5 batches from the method development to the 5 selected 
for validation. 
 
 
 
 
Figure 27: QC 20 method validation chart showing accuracy and precision of validation batches at a 
concentration of 20mg/dl. 
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Figure 27.1: QC 80 method validation chart showing accuracy and precision of validation batches at a 
concentration of 80mg/dl. 
 
 
 
Figure 27.2: QC 200 method validation chart showing accuracy and precision of validation batches at 
a concentration of 200mg/dl.  
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Range of sample concentrations provided by external forensic laboratory: 
 
An accredited forensic laboratory provided 8 B samples to test on the developed GC method to use in 
the validation, the values shown are from the A sample vials and a small difference between the A 
sample values and B sample values are to be expected as were observed in table 36, this was the first 
full batch of all samples analysed. 
Sample: Obtained concentration (mg/dl) 
Blood sample 1 37 
Urine sample 2 484 
Urine Sample 3 277 
Urine sample 4 127 
Blood sample 5 219 
Blood sample 6 139 
Blood sample 7 305 
Urine sample 8 195 
Table 30: Values from A sample analysis carried out by an independent forensic laboratory using an 
independently developed and validated method. Table 36 demonstrates the first batch containing all 
the samples and shows that similar values were attained by this developed method. 
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Repeatability 
Repeatability was tested by analysing the same samples in three batch analyses on three separate 
days featured in tables 33,35 and 37. Differences in concentration were observed due to the nature 
of the metrological ethanol evaporation caused by repeated opening of sample vials. QC data was 
included in tables 34,36 and 38 to demonstrate that inter-run precision has not been lost despite this 
occurrence. The purpose of a repeatability test is to verify that the method can accurately quantify 
known concentrations using calibration standards regularly and to verify the accuracy of the pipetting 
of the analyst. Replicates for the quality control values should fall within a specified limit within the 
validation plan, in this case the limits of a 2.5%CV for any concentration and a 2mg/dl from the 
20mg/dl and 80mg/dl quality controls and a 6mg/dl limit for the 200mg/dl. 
Repeatability batch 1 
 
Table 31: Analytical values for batch 1 repeatability, all values are an average of two duplicates. Urine 
sample 3 was not analysed within this batch due to initial batches of the validation running limited 
samples to minimise ethanol loss with repeated familiarisation batches which occurred at this stage 
with the new pipette system and so is not included. Blood sample 1 is a single replicate due to a file 
corruption of the duplicate.  
 
 
 
Repeatability batch 1 samples 
 
 
Sample Replicate 1 
concentration 
Replicate 2 
concentration 
 
 
Standard 
deviation 
%CV 
(Relative 
Standard 
deviation) 
Concentration 
(mg/dl) 
 
 
Target value 
(mg/dl) 
 
 
% Accuracy 
Blood sample 1 
31 N/A 0.22 0.70 31 37 83.8 
Urine sample 2 
499 487 
 
 
6.43 
 
 
1.30 493 484 101.9 
Urine sample 4 
129 128 
 
 
1.33 
 
 
1.03 128 127 100.8 
Blood sample 5 
213 211 0.78 0.37 212 219 96.8 
Blood sample 6 
131 132 0.69 0.53 132 132 100.0 
Blood sample 7 
309 310 
 
 
1.79 
 
 
0.58 309 305 101.3 
Urine sample 8 
208 196 
 
 
6.15 
 
 
3.04 202 195 103.6 
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Table 32: Analytical QC values for batch 1 repeatability. The term “post sample” refers to the second 
set of QC samples which are run after samples to verify that the intra-run accuracy of the analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
QC values for repeatability batch 1 
 
 
Sample Replicate 1 
concentration 
Replicate 2 
concentration 
 
 
Standard 
deviation 
%CV 
(Relative 
Standard 
deviation) 
Concentration 
(mg/dl) 
 
 
Target value 
(mg/dl) 
 
 
% Accuracy 
QC20 mg/dl 
 
21 21 0.31 1.48 21 20 
 
 
103.3 
QC80 mg/dl 
79 81 0.49 0.61 80 
 
 
80 
 
 
99.5 
QC200 mg/dl 
201 198 1.27 0.64 200 
 
 
200 
 
 
100.2 
QC20 mg/dl 
post sample 
21 21 0.28 1.41 21 20 
 
 
102.6 
QC80 mg/dl 
post sample 
80 81 0.80 1.02 81 80 
 
 
100.84 
QC200 mg/dl 
post sample 
202 201 1.66 0.84 199 
 
 
200 
 
 
99.4 
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Repeatability batch 2 
 
Table 33: Analytical values for batch 2 repeatability. 
 
Table 34: Analytical QC values for batch 2 repeatability. 
Repeatability batch 2 samples 
 
 
Sample Replicate 1 
concentration 
Replicate 2 
concentration 
 
 
Standard 
deviation 
%CV 
(Relative 
Standard 
deviation) 
Concentration 
(mg/dl) 
 
 
Target value 
(mg/dl) 
 
 
% Accuracy 
Blood sample 1 
33 33 
 
 
0.48 
 
 
1.44 
 
 
33 37 89.9 
Urine sample 2 
497 497 
 
 
1.64 
 
 
0.33 
 
 
497 484 102.6 
Urine sample 3 
284 281 
 
 
1.61 
 
 
0.57 
 
 
283 277 102.0 
Urine sample 4 
129 126 
 
 
1.46 
 
 
1.14 
 
 
127 127 100.3 
Blood sample 5 
212 213 
 
 
1.19 
 
 
0.56 
 
 
212 219 97.0 
Blood sample 6 
132 133 
 
 
0.77 
 
 
0.58 
 
 
132 132 100.3 
Blood sample 7 
304 308 
 
2.62 
 
0.86 
 
 
306 305 100.2 
Urine sample 8 
201 198 
 
 
1.57 
 
 
0.79 
 
 
200 195 102.3 
QC values for repeatability batch 2 
 
 
Sample Replicate 1 
concentration 
Replicate 2 
concentration 
 
 
Standard 
deviation 
%CV 
(Relative 
Standard 
deviation) 
Concentration 
(mg/dl) 
 
 
Target value 
(mg/dl) 
 
 
% Accuracy 
QC20 mg/dl 
21 21 
 
 
0.16 1.48 21 20 105.7 
QC80 mg/dl 
80 79 
 
 
0.23 0.61 79 80 99.3 
QC200 mg/dl 
200 200 
 
 
0.46 0.64 200 200 100.0 
QC20 mg/dl 
post sample 
21 21 
 
 
0.06 1.41 21 20 105.1 
QC80 mg/dl 
post sample 
81 80 
 
 
0.97 1.02 81 80 100.9 
QC200 mg/dl 
post sample 
201 200 
 
 
0.99 0.84 200 200 100.1 
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. 
Repeatability batch 3 
 
Table 35: Analytical values for batch 3 repeatability. Due to ethanol loss resulting from a larger 
headspace in the sample vials samples 1, 5 and 6 were no longer suitable for accurate quantitative 
analysis and so were not analysed in this batch. 
 
Table 36: Sample data including QC quantitation for batch 3 of repeatability. All samples passed and 
meet the validation criteria on page 52-53 
 
Repeatability batch 3 samples 
 
 
Sample Replicate 1 
concentration 
Replicate 2 
concentration 
 
 
Standard 
deviation 
%CV 
(Relative 
Standard 
deviation) 
Average 
concentration 
(mg/dl) 
 
 
Target value 
(mg/dl) 
 
 
% Accuracy 
Urine sample 2 
493 475 8.98 1.86 
 
 
484 
 
 
484 100.0 
Urine sample 3 
281 280 0.63 0.22 
 
 
280 
 
 
277 98.9 
Urine sample 4 
125 127 1.23 0.97 
 
 
126 
 
 
127 100.9 
Blood sample 7 
290 292 2.52 0.85 
 
 
291 
 
 
305 103.5 
Urine sample 8 
196 197 0.58 0.30 
 
 
196 
 
 
195 99.3 
QC values for repeatability batch 3 
 
 
Sample Replicate 1 
concentration 
Replicate 2 
concentration 
 
 
Standard 
deviation 
%CV 
(Relative 
Standard 
deviation) 
Concentration 
(mg/dl) 
 
 
Target value 
(mg/dl) 
 
 
% Accuracy 
QC20 mg/dl 
22 21 0.64 2.96 
 
 
22 20 
 
 
103.3 
QC80 mg/dl 
80 79 0.66 0.83 
 
 
80 
 
 
80 
 
 
99.5 
QC200 mg/dl 
200 199 4.50 2.30 
 
 
199 
 
 
200 
 
 
100.2 
QC20 mg/dl 
post sample 
21 21 0.30 1.46 
 
 
21 20 
 
 
102.6 
QC80 mg/dl 
post sample 
80 79 0.63 0.80 
 
 
79 80 
 
 
98.4 
QC200 mg/dl 
post sample 
195 201 3.43 1.73 
 
 
198 
 
 
200 
 
 
99.4 
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Reproducibility 
Reproducibility was tested by having three separate analysts prepare a batch on different days using 
the same samples, as with repeatability results will not be identical, partly due to expected ethanol 
loss and partly due to different analysts preparing each batch. 
Analyst Linearity (r2) column A Linearity (r2) column B 
1 0.99997 0.99995 
2 0.99999 0.99999 
3 0.99990 0.99997 
Table 37: Linearity results taken from the calibration curves from each of the analyst batches. All 
curves are in good agreement and exceed the minimal criteria of 0.998.  
Concentration data for reproducibility experimentation 
 
Table 38: Concentration data obtained by analyst 1.  
 
 
 
Reproducibility batch 1 samples 
 
 
Sample Replicate 1 
concentration 
Replicate 2 
concentration 
 
 
Standard 
deviation 
%CV 
(Relative 
Standard 
deviation) 
Concentration 
(mg/dl) 
 
 
Target value 
(mg/dl) 
 
 
% Accuracy 
Blood sample 1 
33 33 
 
 
0.48 
 
 
1.44 
 
 
33 37 89.9 
Urine sample 2 
497 497 
 
 
1.64 
 
 
0.33 
 
 
497 484 102.6 
Urine sample 3 
284 281 
 
 
1.61 
 
 
0.57 
 
 
283 277 102.0 
Urine sample 4 
129 126 
 
 
1.46 
 
 
1.14 
 
 
127 127 100.3 
Blood sample 5 
212 213 
 
 
1.19 
 
 
0.56 
 
 
212 219 97.0 
Blood sample 6 
132 133 
 
 
0.77 
 
 
0.58 
 
 
132 132 100.3 
Blood sample 7 
304 308 
 
2.62 
 
0.86 
 
 
306 305 100.2 
Urine sample 8 
201 198 
 
 
1.57 
 
 
0.79 
 
 
200 195 102.3 
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Table 39: Reproducibility quality control values obtained by analyst 1. 
 
Table 40: Analyst 2 quantitative values for the second reproducibility analysis, all relative uncertainty 
values are within the prescribed limits for a successful validation. 
QC values for reproducibility batch 1 
 
 
Sample Replicate 1 
concentration 
Replicate 2 
concentration 
 
 
Standard 
deviation 
%CV 
(Relative 
Standard 
deviation) 
Concentration 
(mg/dl) 
 
 
Target value 
(mg/dl) 
 
 
% Accuracy 
QC20 mg/dl 
21 21 
 
 
0.16 1.48 21 20 105.7 
QC80 mg/dl 
80 79 
 
 
0.23 0.61 79 80 99.3 
QC200 mg/dl 
200 200 
 
 
0.46 0.64 200 200 100.0 
QC20 mg/dl 
post sample 
21 21 
 
 
0.06 1.41 21 20 105.1 
QC80 mg/dl 
post sample 
81 80 
 
 
0.97 1.02 81 80 100.9 
QC200 mg/dl 
post sample 
201 200 
 
 
0.99 0.84 200 200 100.1 
Reproducibility batch 2 samples 
 
 
Sample Replicate 1 
concentration 
Replicate 2 
concentration 
 
 
Standard 
deviation 
%CV 
(Relative 
Standard 
deviation) 
Concentration 
(mg/dl) 
 
 
Target value 
(mg/dl) 
 
 
% Accuracy 
Blood sample 1 
33 32 0.55 1.71 
 
 
32 37 87.5 
Urine sample 2 
484 491 2.36 0.48 
 
 
488 484 100.8 
Urine sample 3 
278 284 3.47 1.23 
 
 
281 277 101.5 
Urine sample 4 
127 125 1.04 0.83 
 
 
126 127 99.5 
Blood sample 5 
213 208 3.04 1.44 
 
 
210 219 96.1 
Blood sample 6 
128 131 1.68 1.30 
 
 
130 132 98.1 
Blood sample 7 
303 296 4.09 1.36 
 
 
300 305 98.2 
Urine sample 8 
195 197 1.40 0.72 
 
 
196 195 100.3 
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Table 41: Reproducibility concentration data obtained by analyst 2. The post sample QC200 shows a 
high combined uncertainty and a concentration value close to the lower limit allowed for analysis. This 
sample was a gross error however and the high degree of uncertainty is accounted for by this error, a 
typical analysis like this would be re-run if running forensic samples however for validation purposes 
the error is due to analyst error. 
 
 
 
 
 
 
 
 
 
 
 
 
 
QC values for reproducibility batch 2 
 
 
Sample Replicate 1 
concentration 
Replicate 2 
concentration 
 
 
Standard 
deviation 
%CV 
(Relative 
Standard 
deviation) 
Concentration 
(mg/dl) 
 
 
Target value 
(mg/dl) 
 
 
% Accuracy 
QC20 mg/dl 
21 20 0.54 2.60 
 
 
21 20 104.4 
QC80 mg/dl 
79 81 0.17 0.81 
 
 
21 20 104.9 
QC200 mg/dl 
200 197 0.68 0.85 
 
 
80 80 99.8 
QC20 mg/dl 
post sample 
21 21 1.65 2.08 
 
 
80 80 99.4 
QC80 mg/dl 
post sample 
78 81 1.36 0.69 
 
 
198 200 99.2 
QC200 mg/dl 
post sample 
198 192 2.96 1.52 
 
 
195 200 97.4 
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Table 42: Reproducibility data obtained by analyst 3. All relative uncertainty values are within the 
allowed limits according to the validation plan on page 52-53. Differences in ethanol content between 
batches can be partially attributed to expected ethanol loss. 
 
 
 
 
 
 
 
 
 
 
Reproducibility batch 3 samples 
 
 
Sample Replicate 1 
concentration 
Replicate 2 
concentration 
 
 
Standard 
deviation 
%CV 
(Relative 
Standard 
deviation) 
Concentration 
(mg/dl) 
 
 
Target value 
(mg/dl) 
 
 
% Accuracy 
Blood sample 1 
Insufficient 
volume 
Insufficient 
volume 
Insufficient 
volume 
Insufficient 
volume 
 
Insufficient 
volume 
Insufficient 
volume 
Insufficient 
volume 
Urine sample 2 
489 489 2.36 0.48 
 
 
489 484 101.0 
Urine sample 3 
278 275 3.47 1.23 
 
 
277 277 99.9 
Urine sample 4 
125 127 1.04 0.83 
 
 
126 127 99.0 
Blood sample 5 
203 200 3.04 1.44 
 
 
201 219 92.0 
Blood sample 6 
120 118 1.68 1.30 
 
 
119 132 90.2 
Blood sample 7 
293 288 4.09 1.36 
 
 
291 305 95.3 
Urine sample 8 
192 196 1.40 0.72 
 
 
194 195 99.6 
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Table 43: Quality control values for reproducibility batch 3 demonstrating all values are within the 
prescribed limits for the validation. QC 20 appears to have a high combined and relative uncertainty 
however they still meet pass criteria and can be attributed to differences in analyst skill with the 
method and sampling equipment. 
The results of the reproducibility experimentation show that the QC values passed with three separate 
analysts on three separate days according to the criteria on page 52-53. This demonstrated that the 
method could accurately quantify QC samples. Blood and urine samples also show a consistent 
quantification despite some expected ethanol loss between the analyses which is accounted for due 
to the QC values all achieving a pass. 
 
 
  
QC values for reproducibility batch 3 
 
 
Sample Replicate 1 
concentration 
Replicate 2 
concentration 
 
 
Standard 
deviation 
%CV 
(Relative 
Standard 
deviation) 
Concentration 
(mg/dl) 
 
 
Target value 
(mg/dl) 
 
 
% difference 
20 mg/dl 
21 20 0.50 2.42 
 
 
21 20 104.1 
80 mg/dl 
80 79 0.34 0.34 
 
 
21 20 106.0 
200 mg/dl 
198 198 0.92 1.16 
 
 
79 80 99.4 
20 mg/dl post 
sample 
21 21 0.51 0.65 
 
 
79 80 98.3 
80 mg/dl post 
sample 
79 78 0.69 0.35 
 
 
198 200 99.0 
200 mg/dl post 
sample 
197 198 1.13 0.57 
 
 
197 200 98.7 
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The effect of storage conditions on sample 
stability: 
 
The aim of the stability and storage studies was to assess the accuracy of analysis of samples following 
a potential malfunction with the storage equipment. The study is broken down into several stages, 
firstly a 72-hour quality control sample stability study to identify if a refrigerator breakdown overnight 
would have a significant impact on concentration, extending up to 72 hours. A stability study in blood, 
urine and again quality controls of up to one month. The aim was to determine if poor sample handling 
samples would lead to an effect on ethanol concentration value by testing at three points, zero hours, 
two weeks and one month. The final stage of study involved the experimentation on the effects of 
freezing on urine, blood and quality control samples. The aim of this was to determine if 2 freeze -
thaw cycles had an effect on ethanol concentrations observed. These studies also served to determine 
if there was a difference in ethanol loss observed between three separate matrices. Storage stability 
samples were 0.5ml aliquoted into 1.5ml Agilent these were then and sealed in separate vials. one vial 
per sample per time point was used due to sample limitation. Quality control samples are aliquoted 
as standard and so a fresh aliquot was used per time point. All quality control samples passed in each 
batch featured within the stability study. 
Bench top stability of quality control samples  
The bench top stability study was carried out to verify whether quality control samples left at room 
temperature are stable over a period of 72 hours should they be mishandled or in the event there is 
a malfunction with the refrigeration unit. A long-term stability test was also carried out for up to one 
month to verify the results of this experimentation, as shown in Table 46 where the average 
concentration at zero, 24 and 72 hours are shown. The table shows that all the QC samples still pass 
at 72 hours demonstrating that the quality control samples are stable at room temperature for at least 
72 hours. The extended stability tests will identify how stable quality controls are at room temperature 
for up to one month. 
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Stability of QCs up to 72 hours at room temperature quantitative results: 
 
Table 44: Bench top stability study results for QC ethanol samples for up to 72 hours. 72 hours of room 
temperature exposure had no effect on ethanol concentration. 
Stability of Blood samples 
Blood samples were left at room temperature for two weeks and 1 month to observe the effect of 
room temperature storage on the concentration of ethanol in the samples. A zero-hour control was 
taken to identify the concentration before stability testing began. Of the samples used, blood sample 
1 had a decrease of approximately a 33% decrease (10 mg from 30) between zero hours and one 
month. Sample 5 and 6 did not exhibit a significant drop in ethanol. The ethanol loss observed in 
sample 1 could be attributed to the sample being opened multiple times since receiving the sample 
or in a large headspace for evaporation to occur compared to sample 5 and 6 this could account for 
the higher ethanol loss observed, however the exact cause of this is unknown. All quality control 
samples achieved a pass and were within acceptable parameters. 
Table 45: A summary of column A and B concentration values obtained in the blood stability study. 
Only sample 1 exhibited a significant decrease in ethanol concentration was between zero-hours and 
two-weeks and one month. 
 
 
72-hour benchtop QC stability study 
 
Zero hours 24 hours 
 
 
 
72 hours 
 
 
Expected concentration 
(mg/dl) Replicate 1 Replicate 2 
 
 
 
Replicate 1 
 
 
 
Replicate 2 
 
 
 
Replicate 1 
 
 
 
Replicate 2 
20 20 20 21 21 22 21 
80 79 80 77 79 80 78 
200 199 200 198 198 199 197 
Summary data of stability of blood samples 
Sample Zero hours (mg/dl) 2weeks (mg/dl) 1 Month (mg/dl) 
 Replicate 1 Replicate 2 Replicate 1 Replicate 2 Replicate 1 Replicate 2 
Blood sample 1 33 32 25 25 23 23 
Blood sample 5 203 200 201 195 198 198 
Blood sample 6 120 118 119 117 116 118 
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Table 46: Zero-hour stability quantitation values for blood samples 1, 5 and 6 used in the stability 
storage study. Values shown are taken from the most recent batch of which they were sampled and 
analysed.  
 
Table 47: Two-week blood sample stability quantitation again showing a higher concentration 
decrease in blood sample 1 when compared to that of blood sample 5 and 6 with the quantitation 
being almost 33% lower after two weeks. 
 
 
 
 
 
 
 
Zero hours stability of blood samples 
 
 
Sample Replicate 1 
concentration 
Replicate 2 
concentration 
 
 
Standard 
deviation 
%CV 
(Relative 
Standard 
deviation) 
Concentration 
(mg/dl) 
 
 
Target value 
(mg/dl) 
 
 
% Accuracy 
Blood sample 1 
33 32 0.55 1.71 
 
 
32 37 87.5 
Blood sample 5 
203 200 3.04 1.44 
 
 
201 219 92.0 
Blood sample 6 
120 118 1.68 1.30 
 
 
119 132 90.2 
2-week stability of blood samples 
 
 
Sample Replicate 1 
concentration 
Replicate 2 
concentration 
 
 
Standard 
deviation 
%CV 
(Relative 
Standard 
deviation) 
Concentration 
(mg/dl) 
 
 
Target value 
(mg/dl) 
 
 
% Accuracy 
Blood sample 1 
25 25 0.23 1.21 
 
 
25 
 
 
33 76 
Blood sample 5 
201 195 2.85 1.44 
 
 
198 201 99 
Blood sample 6 
119 117 1.24 1.05 
 
 
118 119 99 
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Table 48: 1-month stability of blood quantitative values, only a slight decrease in ethanol was 
exhibited between the two-week and 1-month time point suggesting that any differences between 
the zero hour and two -week values were partially attributable to expected ethanol loss from sample 
vials being opened. The degree of ethanol loss exhibited from sample 1 was also more like the other 
samples between the aliquoted samples at two weeks and a month which may suggest that the sample 
vial was the source of this ethanol loss. 
Stability of urine samples and quality control samples: 
Urine samples and aliquots of the quality controls were also tested in the same manner as the  blood 
samples were carried out, again as with the blood samples ethanol volumes within the samples 
remains relatively constant between two weeks and a month, a possible cause for the lack of a notable 
change could be the headspace of the vials becoming saturated with ethanol meaning no more 
ethanol can evaporate to fill the headspace above the sample it is not beyond reason to suggest this 
as a cause of the low ethanol loss experienced in the aliquots. All quality control samples passed and 
were within acceptable parameters. 
 
Table 49: Zero- hour urine stability values, all %CVs were within the acceptable range verifying the 
validity of the analysis. 
 
 
1-month stability of blood samples 
 
 
Sample Replicate 1 
concentration 
Replicate 2 
concentration 
 
 
Standard 
deviation 
%CV 
(Relative 
Standard 
deviation) 
Concentration 
(mg/dl) 
 
 
Target value 
(mg/dl) 
 
 
% Accuracy 
Blood sample 1 
23 23 
 
 
0.01 
 
 
0.05 23 
 
 
33 70 
Blood sample 5 
198 198 
 
 
0.21 
 
 
0.11 198 201 99 
Blood sample 6 
116 118 
 
 
 
1.56 
 
 
 
1.33 117 119 98 
Zero hours stability of urine samples 
 
 
Sample Replicate 1 
concentration 
Replicate 2 
concentration 
 
 
Standard 
deviation 
%CV 
(Relative 
Standard 
deviation) 
Concentration 
(mg/dl) 
 
 
Target value 
(mg/dl) 
 
 
% Accuracy 
Urine sample 3 
278 275 3.47 1.23 
 
 
277 277 99.9 
Urine sample 4 
125 127 1.04 0.83 
 
 
126 127 99.0 
Urine sample 8 
192 196 1.40 0.72 
 
 
194 195 99.6 
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Table 50: Values for the benchtop stability study of urine and QC samples at 2 weeks. All values are 
averages of duplicate dual column analyses. All retention time values for both internal standard and 
ethanol were within the set 2% window for identification. All % CV values were within the 2.5% limit 
verifying that there were no errors with sample preparation. 
 
Table 51: Values for the benchtop stability study of urine and QC samples at 1 month. All values are 
averages of duplicate dual column analyses. All retention time values for both internal standard and 
ethanol were within the set 2% window for identification. All %CV values are also within the selected 
2.5% value. 
2-week stability of urine and quality control samples 
 
 
Sample Replicate 1 
concentration 
Replicate 2 
concentration 
 
 
Standard 
deviation 
%CV 
(Relative 
Standard 
deviation) 
Concentration 
(mg/dl) 
 
 
Target value 
(mg/dl) 
 
 
% Accuracy 
Urine sample 3 
278 275 1.63 0.59 
 
 
276 
 
 
277 100 
Urine sample 4 
125 124 0.60 0.48 
 
 
125 
 
 
126 98 
Urine sample 8 
196 195 0.78 0.40 
 
 
196 
 
 
194 100 
QC 20 
21 20 0.40 1.93 
 
 
21 
 
 
20 103 
QC80 
79 78 0.39 0.49 
 
 
78 
 
 
80 98 
QC200 
196 198 0.93 0.47 
 
 
197 
 
 
200 98 
1-month stability of urine and quality control samples 
 
 
Sample Replicate 1 
concentration 
Replicate 2 
concentration 
 
 
Standard 
deviation 
%CV 
(Relative 
Standard 
deviation) 
Concentration 
(mg/dl) 
 
 
Target value 
(mg/dl) 
 
 
% Accuracy 
Urine sample 3 
281 279 1.21 0.43 
 
 
280 
 
 
277 101 
Urine sample 4 
127 127 0.53 0.42 
 
 
127 
 
 
126 100 
Urine sample 8 
195 197 0.92 0.47 
 
 
196 
 
 
194 101 
20 mg stability 
sample 
21 21 0.40 1.90 
 
 
21 
 
 
20 105 
80 mg stability 
sample 
80 80 0.44 0.55 
 
80 
 
 
80 100 
200 mg stability 
sample 
200 198 1.03 0.52 
 
 
199 
 
 
200 100 
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The results of the storage stability show that blood samples are stable at room temperature for up to 
one month showing a slight decrease in ethanol which could be attributed to ethanol loss to 
evaporation, the effect of this loss is relatively small however and is possibly attributed to analytical 
variance. The QC samples left at room temperature appear to be stable for up to one month with 
differences in values quantified being attributable to analytical variances and all values attained would 
still pass should they have been run as QCs in an analysis demonstrating the stability. Urine samples 
exhibit a slight increase in ethanol at the one-month time point, however similarly to the blood 
samples it is only a slight increase, and this could also be attributed to analytical variance, it is possible 
however that this could have been a result of bacterial activity although the increase is not sufficient 
to attribute the values to this. 
Samples of venous blood sourced for freeze-thaw stability study 
Samples of venous blood were sourced by a trained phlebotomist. Two volunteers drank a small 
quantity of alcohol, 1 pint of beer (3.8%) was consumed within one hour, samples were run as 
unknown analytical samples. These were retained for use in the freeze thaw study, ethical approval 
for this was not required. All quality controls used for freeze thaw study batches were within the pass 
range and all batches passed within pre-determined acceptance limits. It was decided that these 
samples would be used instead of the B samples from previous work due to the fact that the B samples 
provided which were several months old. This sampling followed by rapid freeze is a better 
representation of a scenario in which sampled blood for BAC analysis may be frozen inadvertently 
before analysis could take place.  All quality control samples passed and were within acceptable 
parameters 
 
 
Table 52: zero- hour quantitation of venous blood before a freeze-thaw cycle. 
 
 
 
 
 
 
 
Venous blood-quantitation sourced in house for freeze-thaw analysis 
 
 
Sample Replicate 1 
concentration 
Replicate 2 
concentration 
 
 
Standard 
deviation 
%CV 
(Relative 
Standard 
deviation) 
Concentration 
(mg/dl) 
Venous Blood 1 
 
21 21 0.22 1.05 21 
Venous Blood 2 
37 37 0.21 0.56 37 
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Freeze-thaw stability study 
Data obtained from a two-cycle freeze thaw stability experiment demonstrated that the freeze-thaw 
process did not contribute to a significant reduction in ethanol concentrations in blood, urine and in 
the QC samples. This suggests that samples were not significantly adversely affected by the freeze- 
thaw cycle. Table 53 and 54 show the quantitative data obtained in the analyses. Cycle 1 and 2 
concentrations were within 2% of each other which was within the normal range for precision under 
normal analytical conditions. Any deviations between samples were potential analytical variance and 
not something symptomatic of a freeze – thaw cycle. Both sample cycles were removed and thawed 
at the same time cycle 1 samples were thawed and then allowed to come to room temperature before 
being sampled. Cycle 2 samples were allowed to thaw and come to room temperature but were then 
refrozen and thawed the next day for sampling in the same way.  
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Freeze thaw blood and QC samples 
Table 53: Freeze thaw stability values for both blood and quality control samples. Each sample had a 
separate aliquot for each freeze-thaw cycle. All retention time values for both internal standard and 
ethanol were within the set 2% window for identification. All %CV values are also within the selected 
2.5% value. Both cycles were run in one batch, cycle 2 samples were taken out and thawed to room 
temperature the day before the run to enable two freeze thaw cycles to occur before analysis. 
 
 
Freeze-thaw stability of blood and QC samples 
 
 
Sample Replicate 1 
concentration 
Replicate 2 
concentration 
 
 
Standard 
deviation 
%CV 
(Relative 
Standard 
deviation) 
Concentration 
(mg/dl) 
 
 
Target value 
(mg/dl) 
 
 
% Accuracy 
VB 1 cycle 1 
17 17 0.11 0.65 
 
 
17 21 81 
VB 1 cycle 2 
20 20 0.31 1.56 
 
 
20 21 95 
VB 2 cycle 1 
33 33 0.12 0.36 
 
 
33 37 89 
VB 2 cycle 2 
31 32 0.23 0.73 
 
 
32 37 86 
20 mg cycle 1 
20 20 0.33 1.64 
 
 
20 
 
 
20 100 
20 mg cycle 2 
20 20 0.26 1.29 
 
 
20 
 
 
20 100 
80 mg cycle 1 
80 81 0.55 0.69 
 
 
80 
 
 
80 100 
80 mg cycle 2 
80 78 0.98 1.25 
 
 
79 
 
 
80 100 
200 mg cycle 1 
199 197 1.48 0.74 
 
 
198 
 
 
200 99 
200 mg cycle 2 
195 198 1.44 0.73 
 
 
197 
 
 
200 99 
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Table 54: Freeze thaw stability values for urine samples showing both cycle 1 and 2 for comparison of 
ethanol concentrations. Although there were differences between the runs it is not a large enough 
difference to infer any major effect of freeze-thaw on ethanol concentrations, this difference could be 
attributed to sample preparation or analytical variances which occur regardless of the analyst skill. 
 
 
 
 
  
Freeze-thaw stability of urine samples 
 
 
Sample Replicate 1 
concentration 
Replicate 2 
concentration 
 
 
Standard 
deviation 
%CV 
(Relative 
Standard 
deviation) 
Concentration 
(mg/dl) 
 
 
Target value 
(mg/dl) 
 
 
% Accuracy 
Urine 3 cycle 1 
281 281 0.54 0.19 
 
281 
277 101 
Urine 3 cycle 2 
276 279 1.43 0.52 
 
278 
 
 
277 100 
Urine 4 cycle 1 
128 1271 0.36 0.28 
 
 
128 
 
 
126 102 
Urine 4 cycle 2 
124 126 1.11 0.89 
 
 
125 
 
 
126 99 
Urine 8 cycle 1 
196 198 0.88 0.45 
 
 
197 
 
 
194 102 
Urine 8 cycle 2 
198 193 2.21 1.13 
 
 
196 
 
 
194 101 
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It was determined that a reliable method was required to accurately quantify the content of alcohol 
(ethanol) in both blood and urine samples, and to provide separation of the key components found 
within a sample. As this method utilises two columns and detectors the standard was set that at least 
one column must show a full separation of ethanol and any potential interfering substances such as 
acetone. The same requirement was set for the internal standard tertiary-butanol, which was selected 
partially as it elutes in between propan-1-ol and propan-2-ol making it the most suitable for the 
purpose of this method. It provides a good balance between separation of analytes and run time. 
Tertiary butanol was also selected due to the fact it is suitable for post -mortem analysis given it is not 
found as a result of post- mortem bodily changes (Corry 1977). Development testing on method 
conditions began upon installation of the selected columns, the Restek BAC plus 1 and the BAC plus 2.  
These columns were selected for their ability to resolve organic solvents such as alcohols (Restek, 
2018). The method was expected to be able to detect and quantify ethanol at a variety of 
concentrations ranging from 10 mg/dl up to 400mg/dl. The limit of detection was 5 mg/dl. In order to 
achieve these goals, several parameters were optimised and tested.  
Tables 2 and 3 show the selected optimum parameters, the headspace conditioning time, the GC oven 
temperature, run time and the pressure. Compared to methods developed by other researchers (Chun 
et al.2016, Tiscione et al.2011) this method uses a much shorter conditioning and run time. The 
current conditioning time is 5-minutes with a run time of 4 minutes. By contrast, Tiscione et al’s 
method utilised an Agilent D1888 headspace sampler with a GC utilising a Dean’s switch FID and DB-
ALC1 type column which used a 20-minute conditioning and 13.5-minute cycle time. The current 
method developed is 4 times shorter which enables savings in both sample turnover and cost of 
materials such as gases. The method developed also ran an isothermal oven temperature program 
which reduces the run time as the heating and cooling cycle is eliminated. This allows for quicker 
injection of the next sample after the previous sample has been completed. This was especially 
valuable when large volumes of samples were being analysed. 40oC is also a moderately low operating 
temperature and this helps to preserve the column lifetime. Tiscione et al. also utilised a program of 
consecutive conditioning so that the next sample is being conditioned while the GC analysis takes 
place for the sample ahead of it. The rate limiting step then becomes GC run time. Using a ramped 
temperature program requires a longer time frame for the oven to heat and cool thus adding to the 
GC run time thus adding to the GC run time. The method described in this project also utilised a 
conditioning time lag of approximately two minutes rather than the full 5 minutes. 
The R2 value for linearity demonstrated by Tiscione et al’s method was 1.000 whereas the average 
attained in the validation process of this method was 0.9999, both methods far exceed the 0.998 
requirement. The method developed by Chun et al. is still sufficient for the analytical standards with 
an average linearity of 0.999, the linearity of Chun et al’s method was also tested in two matrices, 
deionised water and brain tissue. Sample preparation of brain tissue was carried out by diluting human 
brain tissue 1:4 in deionised water and homogenised, this was then used in system suitability testing 
by adding the same solution used to the homogenate (Chun et al., 2016).  
Separation and system suitability are also comparable between the two other studies and the method 
described in this project, Tiscione et al. demonstrated with their method that there was a separation 
of ethanol from the surrounding compounds, in this case the elution order was different due to 
different column types being used and was lacking analytes such as acetaldehyde and tertiary butanol. 
It was highlighted however from the chromatograms that on this analysis acetone and n-propanol 
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eluted closely with insufficient baseline separation in a similar manner to ethanol and acetone 
featured in this method’s development stage (table, 11) which demonstrated the difficulty of 
analysing ethanol in samples with acetone present. The second detector used in Tiscione et al’s 
method was a mass spectrometer which provided a similar retention time and chromatography. The 
mass spectra provided fragmentation patterns of each analyte tested. This method also utilised n-
propanol as the internal standard suggesting an analysis of ethanol with the presence of acetone will 
be difficult due to possible co-elution of ethanol and the n-propanol internal standard which may 
interfere with the quantitation of ethanol. This contrasted with the results of this project, which relied 
on separation of acetone and ethanol from a second column with differing chemistry with differential 
polarities and two identical detectors.  
A study by Schlatter et al. utilising a Thermo Finnigan model GC FID system coupled with Uptibond 1 
premium type column had a total run time of 20 minutes. This run time achieved clear baseline 
separation of ethanol and acetone, and tertiary butanol however, acetaldehyde and methanol still 
elute closely but to a lesser extent than in this method, although as stated these are typically not 
analysed in road traffic blood alcohol concentration analysis and so full baseline separation is not vital 
(Schlatter, 2014). This method was derived from another method (Pontes et al.2009) which utilised 
the same Thermo Finnigan type GC FID but with a CPWAX 57CB type column and tested the separation 
of analytes in different matrices including blood, vitreous humour, urine and cell culture media. This 
method obtained a different elution order and separation pattern to the previous methods described. 
Pontes et al’s method demonstrated acetone eluted before ethanol and had full baseline separation 
(Pontes et al. 2009), the separation mixture also contained acetonitrile which was not included in the 
system suitability solution tested in the method developed in this project. The method does however 
include tertiary butanol and propan-2-ol which are not included within Pontes et al’s method. This 
means that although acetone has a clearer separation it is difficult to fully compare the separation 
profiles of the two methods due to different analytes being included in the experimentations. 
Lewis et al. utilised the same BAC plus 2 type column used in this validation plan and achieved a similar 
co-elution of ethanol and acetone. This suggested that a limitation of the column is an inability to 
separate acetone and ethanol using analytically viable parameters despite the column being 
advertised as being able to clearly separate the two compounds. This also demonstrates that it is not 
a method limitation and is more likely attributed to the column than the parameters selected. It is for 
this reason that optimum conditions were selected, and it was decided that in the event of an acetone 
being present in a case sample the second column (the BAC plus 1) will be used for quantification  by 
running two sets of duplicates,(Lewis et al, 2004). Lewis et al. used a flow rate of 20 ml/min whereas 
this method used a flow rate of almost 10 times lower at 2.78 ml/min and despite this the separation 
of acetone did not improve markedly. This suggests that there is a proportional effect of pressure on 
acetone and ethanol rather than a differential effect. Chun et al. also used a BAC plus 2 column in their 
method and used a flow rate of 16.8ml/min yet still achieved the same level of separation of acetone 
and ethanol showing an almost identical chromatogram of a system suitability solution to the one 
featured in figure 17, given that three separate and independent methods all exhibit the same 
limitation it is unlikely due to specific limitations of this method.  
The current method was developed and validated according to the pre-determined validation plan 
which is in line with UKAS guidelines for best practice in ISO17025 accreditation. The method was 
successfully validated, and the second objective of the experimentation which was stability studies 
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was then addressed. The outcome of these studies showed that blood, urine and quality control 
samples are all stable at room temperature for at least one month. Although they were all stable for 
up to one month, it is still advisable that samples are not kept at room temperature for longer than is 
required for the samples to reach room temperature and the analytical samples to be prepared for 
analysis. Further, it was determined that urine and QC samples that had been deliberately frozen still 
provided accurate quantitative results although again it is not advised that samples are deliberately 
frozen. These studies provided a perspective of samples that were mishandled to identify how samples 
may behave should there be a storage malfunction. Of blood samples tested, three out of the four 
samples tested exhibited a decrease of approximately 5 mg/dl which could possibly mean that blood 
samples are less stable when frozen regarding blood alcohol concentrations, the difference between 
cycle 1 and cycle 2 freeze-thaw was less pronounced and so the results are inconclusive. A loss of 
ethanol could not have occurred between the sampling of the zero-hour batch and the preparation of 
freeze-thaw aliquots due to these being taken at the same time and further investigation would need 
to be carried out in order to identify the exact reason for this result. 
A potential limitation of this method which is currently unexplored is the suitability of this method to 
analyse post-mortem samples as well as other biological matrices such as vitreous humour. Post-
mortem samples are more difficult to analyse and a study by Sylvester et al. demonstrated this 
showing different alcohol concentrations depending on where the blood was sampled from on the 
body, as well as a difference between blood and vitreous humour (Sylvester et al., 1998). Further 
investigation into this would be required to determine the method suitability for post-mortem analysis 
with regards to acetone formation and post-mortem samples exhibiting acetone. It is also suggested 
that ethanol is produced as a product of putrefaction which may artificially raise the alcohol content 
of a sample fluid, in addition substances such as acetaldehyde an n-propanol may also be produced 
post-mortem (Corry, 1977). The method has been validated to accurately quantify samples of ethanol 
however and so the method should be suitable to test post-mortem samples accurately and the 
limiting factor of these samples will be the uncertainty of sampling techniques rather than a limitation 
of the method. It is also shown that acetone can be separated on one column and so the method is 
anticipated to be accurate enough to analyse post-mortem samples. 
Potential future expansions and improvements which could be made to this method include the 
possibility of changing the carrier gas to nitrogen which would reduce the running cost of the method 
as nitrogen is a cheaper gas to source compared to helium. The method is currently operating a 
moderately low linear velocity which may be suitable for the use of nitrogen as a carrier gas, this could 
also be provided using a nitrogen generator further reducing running costs of the method. In addition 
to this, a different secondary column could be utilised such as the CPWAX 57CB which was shown to 
resolve ethanol and acetone more effectively than the current BAC 2 type column installed. This would 
solve the current limitation of acetone and ethanol co-eluting on one column enabling a reduction in 
sample volume required for analysis of samples containing acetone. These improvements would 
require the method to be re-validated however and so the assessment of the benefits compared to 
the time required to re-validate the method would be required before any changes were made to the 
current method. Further experimentation that could be performed using this method include using 
smaller sampling sizes of 10, 5 and 1 μl of sample and accordingly smaller internal standard samples 
at 100, 50 and 10 μl respectively to investigate the viability of this method using reduced sample 
volume and IS solution. This method is also expected to undergo inter-laboratory PT testing in 2019 
which was not possible to date. 
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To conclude, the method developed and validated in this thesis demonstrated a similar performance 
to other validated blood alcohol GC-FID methods including methods utilising the same column types. 
These studies also provided evidence that the BAC 2 column shared the same limitations and verified 
that the optimum parameters selected were valid and that it would have proven to be unnecessary 
and an inappropriate usage of laboratory time attempting to achieve full separation on this column. 
This study also highlighted that the method linearity is well within industry standards and this also 
demonstrates that the degree of accuracy of calibration range is above what is acceptable for forensic 
analysis of blood and urine alcohol thus fulfilling the stated method purpose and objectives. The initial 
blood and urine alcohol values attained by this method show similar values to the values provided by 
the external accredited laboratory, demonstrating that blood and urine samples can be accurately 
quantified by the method. This method also meets the requirement set out by the UKAS code of 
conduct that a method should demonstrate compatibility of results obtained compared to other 
analyst results using different equipment/methods. These UKAS guidelines for the validation of 
measurement-based methods state that the validation plan should ensure that parameters are tested 
a) using a competent analyst with experience in the field of work of the study to be able to make 
decisions based on the observations made as the study progresses; and b) using equipment that is 
within specification, calibrated and functioning correctly (Renninson, 2011). Both are satisfactorily 
met by the validation plan with repeatability and reproducibility demonstrating that both the analyst 
undertaking the validation is competent and that the equipment is to standard when used by different 
analysts.  
The guidelines also outline the functional and performance characteristics which a method should 
exhibit which include the competence of the analyst, which has been demonstrated In addition to a 
number of other  considerations such as; environmental constraints, sample size and handling, sample 
homogeneity, the ability of the sampling process to provide a representative sample of the exhibit, 
the efficiency of recovery of the analyte during sample preparation for analysis, the ability to detect 
the presence or absence of analyte in a sample, minimum quantity of the analyte that can be reliably 
detected (LOD) and accurately quantified (LOQ), the identification/measurement of the analyte 
relates to the analyte alone and is not influenced by an interfering substance or compromised by a 
matrix, the results are reliable, consistent and include an uncertainty measurement, compatibility of 
results obtained by other analysts using different equipment and methods and the limitations of 
applicability (Renninson, 2011). These guidelines were met and addressed in either the sample 
preparation stage with sample size, homogeneity and handling being addressed in the sample 
preparation stage and the recovery of analytes during sample preparation being demonstrated with 
consistent accurate QC values which also shows that the method is both accurate and precise. QC 
charts plotted for all QC concentrations demonstrate that none of the representative values fall 
outside of the control limits. QC results as well as the %CV values were also within acceptable limits 
according to the validation plan which further demonstrated the accuracy and precision of the 
method. An uncertainty measurement was also included in all results attained in accordance with the 
guidelines on best practice with the relative uncertainty being selected for use in unknown samples 
and both relative and expanded uncertainties being used for QC samples which have certificates of 
analysis allowing for the expanded uncertainty to be calculated.  
The limits of detection and quantitation were tested and shown in accordance with the codes of 
conduct and acetone, the major interfering substance encountered in the development and validation 
process was separated from ethanol on one column as required by the method objective and the code 
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of practice. All validation parameters achieved a pass thus the objective of validating a method 
capable of accurately quantifying and detecting ethanol in both blood and urine was successfully 
achieved. Stability of samples was also investigated, and matrix stability studies verified the stability 
of samples for analysis whilst also highlighting that samples may be stable, but it is imperative that 
samples are stored correctly to avoid the risk of samples being exposed to unfavourable conditions 
which may lead to inaccuracies in the analysis. The method that has been developed  can accurately 
detect ethanol in a range of 5mg/dl-400mg/dl and this method will be used to provide casework 
analytical services in UK Road Traffic Act cases. 
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